<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Primary Congenital Glaucoma - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjXxfAce32@3GyyXFaAAAAABc","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Primary_Congenital_Glaucoma","wgTitle":"Primary Congenital Glaucoma","wgCurRevisionId":89564,"wgRevisionId":89564,"wgArticleId":101,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma","Pediatric Ophthalmology/Strabismus"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Primary_Congenital_Glaucoma","wgRelevantArticleId":101,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],
"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},
"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Primary congenital glaucoma (PCG) is a rare disease due to genetically-determined abnormalities in the trabecular meshwork and anterior chamber angle resulting in elevated intraocular pressure (IOP), without other ocular or systemic developmental anomalies. Other terms have been used previously to describe this entity, including trabeculodysgenesis, goniodysgenesis and primary infantile glaucoma, however the term PCG replaces these in the 2013 International Classification of Childhood Glaucoma.&amp;#91;2&amp;#93; There are three variants based on the age of presentation as follows:"/>
<meta name="date" content="2023-02-09"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Primary Congenital Glaucoma" href="/w/index.php?title=Special:ExportRDF/Primary_Congenital_Glaucoma&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Primary_Congenital_Glaucoma rootpage-Primary_Congenital_Glaucoma layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Primary+Congenital+Glaucoma" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Primary+Congenital+Glaucoma" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzz0468g"></button>
					<div class="collapse navbar-collapse hbpzz0468g" id="hbpzz0468g">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Primary_Congenital_Glaucoma" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Primary_Congenital_Glaucoma&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Primary_Congenital_Glaucoma&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Primary_Congenital_Glaucoma&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Primary_Congenital_Glaucoma&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Primary_Congenital_Glaucoma#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Primary Congenital Glaucoma</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Robert.A.Clark.CMT" title="User:Robert.A.Clark.CMT">Robert A. Clark M.D.</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Amanda.Ely" title="User:Amanda.Ely">Amanda Ely, M.D.</a>,&#160;<a href="/User:Bushra.Rahman" title="User:Bushra.Rahman">Bushra Rahman</a>,&#160;<a href="/User:Mandy.Wong" title="User:Mandy.Wong">Mandy Oi Man Wong, MBBS, FRCSEd(Ophth)</a>,&#160;<a href="/User:Sharon.F.Freedman" title="User:Sharon.F.Freedman">Sharon F. Freedman, MD</a>,&#160;<a href="/User:Alex.Kozak.AAO" title="User:Alex.Kozak.AAO">Alex Kozak</a>,&#160;<a href="/User:K.David.Epley.SEC" title="User:K.David.Epley.SEC">K. David Epley, M.D.</a>,&#160;<a href="/User:Daniel.B.Moore" title="User:Daniel.B.Moore">Daniel B. Moore, MD</a>,&#160;<a href="/User:John.Davis.Akkara" title="User:John.Davis.Akkara">Dr John Davis Akkara (MBBS, MS, FAEH, FMRF)</a>,&#160;<a href="/User:Allison.R.Loh" title="User:Allison.R.Loh">Allison R. Loh, MD</a>,&#160;<a href="/User:Joobin.Khadamy" title="User:Joobin.Khadamy">Joobin Khadamy, MD</a>,&#160;<a href="/User:Grace.Prakalapakorn" title="User:Grace.Prakalapakorn">S. Grace Prakalapakorn, MD, MPH</a>,&#160;<a href="/User:Ann.Shue" title="User:Ann.Shue">Ann Shue</a>,&#160;<a href="/User:Robert.A.Clark.CMT" title="User:Robert.A.Clark.CMT">Robert A. Clark M.D.</a>,&#160;<a href="/User:Allison.Umfress" title="User:Allison.Umfress">Allison Umfress, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Allison.Umfress" title="User:Allison.Umfress">Allison Umfress, MD</a>,&#32;<a href="/User:Daniel.B.Moore" title="User:Daniel.B.Moore">Daniel B. Moore, MD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Daniel.B.Moore" title="User:Daniel.B.Moore">Daniel B. Moore, MD</a> on February 10, 2023.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Primary_Congenital_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Primary_Congenital_Glaucoma&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table>  </div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div class="infobox vertical">
<div class="info-section vertical" style="margin-bottom: 10px;">
<div class="info-section-header">Primary Congenital Glaucoma
  </div>
<div class="info-section-body">
  </div>
</div>
<div class="info-section vertical" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/File:AA0_5639.png" class="image"><img alt="Congenital glaucoma, cloudy corneas." src="/w/images/1/c/c4/AA0_5639.png" decoding="async" width="480" height="211" /></a> 
     </div>
<div class="info-section-body">Congenital glaucoma, cloudy corneas. © 2019 American Academy of Ophthalmology <sup id="cite_ref-1" class="reference"><a href="#cite_note-1">&#91;1&#93;</a></sup>     
     </div>
</div>
<div class="info-section horizontal" style="margin-bottom: 10px;">
<div class="info-section-header"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/Diseases_Database">DiseasesDB</a>
        </div>
<div class="info-section-body"><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb1778.htm">1778</a>
        </div>
</div>
<div class="info-section horizontal" style="margin-bottom: 10px;">
<div class="info-section-header"><a rel="nofollow" class="external text" href="http://en.wikipedia.org/wiki/OMIM">OMIM</a>
        </div>
<div class="info-section-body"><a rel="nofollow" class="external text" href="http://omim.org/entry/231300">231300</a>
        </div>
</div>
</div>
<p><br />
</p>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Disease_Entity"><span class="tocnumber">1</span> <span class="toctext">Disease Entity</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Disease_Overview_and_Definition"><span class="tocnumber">1.1</span> <span class="toctext">Disease Overview and Definition</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Demographics"><span class="tocnumber">1.2</span> <span class="toctext"><b>Demographics</b></span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Etiology"><span class="tocnumber">1.3</span> <span class="toctext">Etiology</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Risk_Factors"><span class="tocnumber">1.4</span> <span class="toctext">Risk Factors</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#General_Pathology"><span class="tocnumber">1.5</span> <span class="toctext">General Pathology</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Pathophysiology"><span class="tocnumber">1.6</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Primary_prevention"><span class="tocnumber">1.7</span> <span class="toctext">Primary prevention</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Symptoms"><span class="tocnumber">1.8</span> <span class="toctext">Symptoms</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Signs"><span class="tocnumber">1.9</span> <span class="toctext">Signs</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-11"><a href="#Diagnosis"><span class="tocnumber">2</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2 tocsection-12"><a href="#History"><span class="tocnumber">2.1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#Physical_examination"><span class="tocnumber">2.2</span> <span class="toctext">Physical examination</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Clinical_diagnosis"><span class="tocnumber">2.3</span> <span class="toctext">Clinical diagnosis</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Diagnostic_procedures"><span class="tocnumber">2.4</span> <span class="toctext">Diagnostic procedures</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Laboratory_test"><span class="tocnumber">2.5</span> <span class="toctext">Laboratory test</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Differential_diagnosis"><span class="tocnumber">2.6</span> <span class="toctext">Differential diagnosis</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-18"><a href="#Management"><span class="tocnumber">3</span> <span class="toctext">Management</span></a>
<ul>
<li class="toclevel-2 tocsection-19"><a href="#General_treatment"><span class="tocnumber">3.1</span> <span class="toctext">General treatment</span></a></li>
<li class="toclevel-2 tocsection-20"><a href="#Medical_therapy"><span class="tocnumber">3.2</span> <span class="toctext">Medical therapy</span></a></li>
<li class="toclevel-2 tocsection-21"><a href="#Surgery"><span class="tocnumber">3.3</span> <span class="toctext">Surgery</span></a></li>
<li class="toclevel-2 tocsection-22"><a href="#Surgical_follow_up"><span class="tocnumber">3.4</span> <span class="toctext">Surgical follow up</span></a></li>
<li class="toclevel-2 tocsection-23"><a href="#Complications"><span class="tocnumber">3.5</span> <span class="toctext">Complications</span></a></li>
<li class="toclevel-2 tocsection-24"><a href="#Prognosis"><span class="tocnumber">3.6</span> <span class="toctext">Prognosis</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-25"><a href="#Additional_Resources"><span class="tocnumber">4</span> <span class="toctext">Additional Resources</span></a></li>
<li class="toclevel-1 tocsection-26"><a href="#References"><span class="tocnumber">5</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Disease_Entity">Disease Entity</span></h1>
<p>Primary congenital glaucoma (PCG) is a rare disease due to genetically-determined abnormalities in the trabecular meshwork and anterior chamber angle resulting in elevated intraocular pressure (IOP), without other ocular or systemic developmental anomalies. Other terms have been used previously to describe this entity, including trabeculodysgenesis, goniodysgenesis and primary infantile glaucoma, however the term PCG replaces these in the 2013 International Classification of Childhood Glaucoma.<sup id="cite_ref-:1_2-0" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> There are three variants based on the age of presentation as follows: 
</p><p>1) newborn onset (0-1 month)
</p><p>2) infantile onset (&gt;1-24 months)
</p><p>3) late onset or late-recognized (&gt;24 months)
</p><p>4) spontaneously arrested cases (very
rare, classic findings of eye stretching including Haab striae with normal IOP; must follow as glaucoma suspects nonetheless)
</p><p>PCG commonly presents between the ages of 3-9 months, but the most severe form is the newborn onset. Elevated
IOP is associated with the classic “triad” of symptoms (photophobia,
epiphora and blepharospasm), which occurs due to rapid expansion of the child’s
eye causing buphthalmos (Greek = “ox eye”), corneal enlargement, horizontal or
oblique breaks in Descemet membrane (Haab striae) and subsequent corneal edema
and opacification. If Haab striae and buphthalmos are seen without elevated
IOP, optic nerve cupping or corneal edema, then the patient has <i>spontaneously arrested PCG.&#160;</i><sup id="cite_ref-:1_2-1" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup>
</p><p>The prognosis for
children with PCG is quite variable, with some achieving good vision, while
others go blind. While PCG accounts for less than 0.01% of all patients with
eye diseases, it has been blamed for 
 5% of childhood blindness worldwide.<sup id="cite_ref-:0_3-0" class="reference"><a href="#cite_note-:0-3">&#91;3&#93;</a></sup> Vision loss is secondary to corneal scarring or
optic nerve damage, and often amblyopia in asymmetric or unilateral cases.
Surgical management is the primary treatment modality. If IOP is controlled,
vision in the better eye ultimately can be 20/60 or better.<sup id="cite_ref-:12_4-0" class="reference"><a href="#cite_note-:12-4">&#91;4&#93;</a></sup><sup id="cite_ref-:13_5-0" class="reference"><a href="#cite_note-:13-5">&#91;5&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Disease_Overview_and_Definition">Disease Overview and Definition</span></h2>
<p>PCG is the
most common form of primary childhood glaucoma, and is one, of two primary childhood
glaucomas, that presents in children younger than 4 years of age (the other primary
childhood glaucoma being <a href="/Juvenile_open_angle_glaucoma" class="mw-redirect" title="Juvenile open angle glaucoma">juvenile open angle glaucoma</a>). PCG and other childhood glaucomas presenting in infancy
may present with one or more of the classic triad of <i>epiphora, photophobia</i> and<i></i>
<i>blepharospasm</i>; however if ocular or systemic abnormalities, either
congenital or acquired, are also present, then PCG can be ruled out, and
secondary childhood glaucomas need to be considered (i.e. <a href="/Axenfeld_Rieger_Syndrome" title="Axenfeld Rieger Syndrome">Axenfeld-Rieger syndrome</a>, <a href="/Aniridia" title="Aniridia">aniridia</a>, <a href="/Peters%27_Anomaly" class="mw-redirect" title="Peters&#39; Anomaly">Peters anomaly</a>, <a href="/Persistent_hyperplastic_primary_vitreous" class="mw-redirect" title="Persistent hyperplastic primary vitreous">persistent fetal vasculature</a>, <a href="/Oculodermal_Melanocytosis_(Nevus_of_Ota)" title="Oculodermal Melanocytosis (Nevus of Ota)">oculodermal melanocytosis</a>, <a href="/Posterior_Polymorphous_Corneal_Dystrophy" title="Posterior Polymorphous Corneal Dystrophy">posterior polymorphous dystrophy</a>, <a href="/Microphthalmos" title="Microphthalmos">microphthalmos</a>, microcornea, <a href="/Ectopia_Lentis" title="Ectopia Lentis">ectopia lentis</a>, <a href="/Sturge-Weber_Syndrome_and_Secondary_Glaucoma" title="Sturge-Weber Syndrome and Secondary Glaucoma">Sturge-Weber syndrome,</a> <a href="/Lowe_Syndrome" title="Lowe Syndrome">Lowe syndrome</a>, <a href="/Ocular_manifestations_of_phakomatoses_(Neurocutaneous_Syndromes)" class="mw-redirect" title="Ocular manifestations of phakomatoses (Neurocutaneous Syndromes)">neurofibromatosis,</a> <a href="/Traumatic_Glaucoma" title="Traumatic Glaucoma">trauma</a>, <a href="/Uveitic_Glaucoma" title="Uveitic Glaucoma">inflammation</a>, <a href="/Steroid_induced_Glaucoma" class="mw-redirect" title="Steroid induced Glaucoma">steroid-induced</a>, <a href="/Juvenile_Xanthogranuloma" title="Juvenile Xanthogranuloma">tumors</a>, <a href="/Retinopathy_of_Prematurity" title="Retinopathy of Prematurity">retinopathy of prematurity,</a> <a href="/Cataracts_in_Children,_Congenital_and_Acquired" title="Cataracts in Children, Congenital and Acquired">glaucoma following cataract surgery)</a>.
</p><p>Due to the elasticity of the eye in
young children, the 2013 International Classification System for Childhood
Glaucoma defined childhood glaucoma as irreversible or reversible damage to the
whole eye (not just the optic nerve as glaucoma is defined for adults). Thus, additional important clinical signs in PCG, besides
elevated IOP and optic nerve cupping, are <i>corneal enlargement and clouding, Haab striae, </i>and<i> buphthalmos. </i>Not all signs are always
present, however, and other parts of the eye also stretch with elevated IOP. Diagnosis of
PCG can be delayed if corneas remain clear, despite being enlarged, and bilateral
PCG can be missed if signs and symptoms are mild in one eye. Irreversible vision
loss results if elevated IOP is untreated or uncontrolled in PCG. Optic nerve
damage occurs, and focal corneal edema overlying Haab striae, which can be
single or multiple, can lead to permanent corneal scarring and opacification. This corneal scarring
can obscure the visual axis or cause astigmatism with or without refractive amblyopia.
Amblyopia may also develop due to optic nerve damage, anisometropia, strabismus
or a combination.
</p>
<h2><span class="mw-headline" id="Demographics"><b>Demographics</b></span></h2>
<p>Incidence of PCG varies by geographic location; rates can be as high as 1 in 1250 in some Eastern Europeans or as low as 1 in 20000 in Western countries. The rate is 5-10 times higher in children from consanguineous relationships.<sup id="cite_ref-:14_6-0" class="reference"><a href="#cite_note-:14-6">&#91;6&#93;</a></sup> 
It is bilateral in 65-80% of cases.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">&#91;7&#93;</a></sup> <sup id="cite_ref-:0_3-1" class="reference"><a href="#cite_note-:0-3">&#91;3&#93;</a></sup>Male to female ratio
is 3 to 2 in the United States and Europe.  <sup id="cite_ref-:4_8-0" class="reference"><a href="#cite_note-:4-8">&#91;8&#93;</a></sup>In Japan, a study
compared PCG patients with and without <i>CYP1B1</i>
mutations and found a ratio of male to female incidence of 6:5 in
patients with <i>CYP1B1 </i>mutations, and 19:2 in those
without <i>CYP1B1</i> mutations.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9">&#91;9&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Etiology">Etiology</span></h2>
<p>Most PCG cases are sporadic (with no
family history), however, about 10-40% are familial, with an autosomal recessive
inheritance pattern and penetrance varying from 40-100%. <sup id="cite_ref-:1_2-2" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup>
Autosomal dominant inheritance has also been reported. <sup id="cite_ref-:2_10-0" class="reference"><a href="#cite_note-:2-10">&#91;10&#93;</a></sup>Five loci have been
identified by linkage analyses: GLC3A (located on choromosome 2p22-p21), GLC3B
(1p36.2-p36.1), GLC3C (14q24.3), GLC3D (14q24.2-q24.3, not overlapping with
GLC3C), and GLC3E (9p21).<sup id="cite_ref-:0_3-2" class="reference"><a href="#cite_note-:0-3">&#91;3&#93;</a></sup><sup id="cite_ref-:3_11-0" class="reference"><a href="#cite_note-:3-11">&#91;11&#93;</a></sup> 
</p><p>Thus far, a gene associated with PCG has been identified in three of these five
loci. Further details are below.  
</p><p>The GLC3A loci contains the
cyctochrome P4501B1 (<i>CYP1B1)</i> gene,
which was the first reported PCG-causing gene. It codes for an enzyme that
metabolizes compounds vital for the developing eye, such as fatty acids and vitamins<sup id="cite_ref-:14_6-1" class="reference"><a href="#cite_note-:14-6">&#91;6&#93;</a></sup>, and is expressed in fetal
and adult neuroepithelium and ciliary body. <sup id="cite_ref-:1_2-3" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup><sup id="cite_ref-12" class="reference"><a href="#cite_note-12">&#91;12&#93;</a></sup>Severe trabecular
meshwork atrophy is seen in mouse models deficient of <i>CYP1B1</i>. 
<sup id="cite_ref-13" class="reference"><a href="#cite_note-13">&#91;13&#93;</a></sup>In zebrafish, <i>CYP1B1</i> has been found
to indirectly affect neural crest migration to the anterior segment and angle
by playing a role in ocular fissure closure. 
<sup id="cite_ref-14" class="reference"><a href="#cite_note-14">&#91;14&#93;</a></sup> While the exact mechanism by which <i>CYP1B1 </i>mutations
causes PCG is unknown, we know that levels of a protein product of this gene are inadequate for appropriate embryogenic ocular development, resulting in goniodysgenesis. A twin study demonstrated that CYP1B1 gene activity may be implicated in a common pathway PCG, juvenile open-angle glaucoma, and primary open angle glaucoma. Recent studies propose that the mutation may also interfere with the ability of retinal ganglion cells to respond to the stress generated by high IOP and the resultant increase in reactive oxygen species.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup><sup id="cite_ref-16" class="reference"><a href="#cite_note-16">&#91;16&#93;</a></sup><i>CYP1B1</i> mutations are associated with 15-20% of PCG cases in Japan and the United States, 75-100% of cases in Saudi Arabia, and all cases in Slovakia Roma. <sup id="cite_ref-:15_17-0" class="reference"><a href="#cite_note-:15-17">&#91;17&#93;</a></sup><sup id="cite_ref-:16_18-0" class="reference"><a href="#cite_note-:16-18">&#91;18&#93;</a></sup> 
</p><p>The GLC3D locus contains latent
transforming growth factor beta binding protein 2 (<i>LTBP2)</i>. <i>LTBP2</i> is
expressed in trabecular meshwork and ciliary processes however its role in the
eye is unknown.<sup id="cite_ref-:15_17-1" class="reference"><a href="#cite_note-:15-17">&#91;17&#93;</a></sup> In nonocular
tissues, it is involved in tissue repair and cell adhesion. <sup id="cite_ref-:16_18-1" class="reference"><a href="#cite_note-:16-18">&#91;18&#93;</a></sup><sup id="cite_ref-19" class="reference"><a href="#cite_note-19">&#91;19&#93;</a></sup> <i>LTBP2</i> null mutations have been reported in consanguineous Iranian
and Pakistani families, and Slovakian Roma with PCG. Homozygosity for a variant
of an <i>LTBP2</i> mutation was associated
with worse outcomes even while undergoing more surgical interventions.<sup id="cite_ref-:0_3-3" class="reference"><a href="#cite_note-:0-3">&#91;3&#93;</a></sup><sup id="cite_ref-:2_10-1" class="reference"><a href="#cite_note-:2-10">&#91;10&#93;</a></sup> 
</p><p>GLC3E contains the tunica interna
endothelial cell kinase (<i>TEK</i>, also
known as <i>TIE2</i>) gene. The angiopoietin/TEK
(ANGPT/TEK) signaling pathway is required in Schlemm canal development, and
includes 3 ligands (ANGPT1, ANGPT2, and ANGPT4) and 2 receptors (TEK and TIE). <i>TEK</i>-knockout mice can have no Schlemm
canal and <i>TEK</i>-hemizygous mice have a
severely underdeveloped Schlemm canal.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20">&#91;20&#93;</a></sup> Additionally,
<i>ANGPT1</i> mutations have been identified
in a few PCG patients who do not have other known PCG-causing genes, revealing
another member of the ANGPT/TEK signaling pathway that may be a cause of PCG.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup> A recent study conducted in China re-demonstrated TEK mutations as causative in PCG. In patients with the loss of function p.C264F variant located in the ectodomain of TIE2, it is thought that disruption of disulfide bond formation leads to misfolding and subsequent instability of protein products. The p.L504P variant in the same ectodomain appears to replace a leucine with a proline at a critical location in a beta-pleated sheet, preventing proper intra-strand hydrogen bonding.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup>
</p><p>Lastly, though not associated with
the above loci, but originally associated with juvenile open angle glaucoma and
primary open angle glaucoma, the myocilin/trabecular meshwork-induced
glucocorticoid response protein (<i>MYOC</i>)
gene on chromosome 1q24 may also explain a small proportion of PCG cases, up to
5.5%.<sup id="cite_ref-:0_3-4" class="reference"><a href="#cite_note-:0-3">&#91;3&#93;</a></sup><sup id="cite_ref-:3_11-1" class="reference"><a href="#cite_note-:3-11">&#91;11&#93;</a></sup><sup id="cite_ref-23" class="reference"><a href="#cite_note-23">&#91;23&#93;</a></sup>
</p><p>PCG patients may have one or more
genes affected, and the previously discussed genes may regulate or interact
with each other.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24">&#91;24&#93;</a></sup> <i>CYP1B1</i> may play a role as a modifier gene for <i>MYOC</i> expression, <sup id="cite_ref-25" class="reference"><a href="#cite_note-25">&#91;25&#93;</a></sup>
and a digenic mode of inheritance has been considered for <i>CYP1B1</i> and <i>MYOC</i>,<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup> and <i>CYP1B1</i> and <i>TEK</i>.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup> 
</p><p>Currently, the chance of identifying
a genetic cause is 40% when genetic testing is done.<sup id="cite_ref-:0_3-5" class="reference"><a href="#cite_note-:0-3">&#91;3&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Risk_Factors">Risk Factors</span></h2>
<p>The only known risk factors are
genetic - consanguinity and affected siblings. Parents of PCG patients should
be aware that the chance of a second child with PCG is a small but real risk
that usually is no more than 3%. If two children have the disease, then the
risk of subsequent children increases to as high as 25%, with the assumption of
autosomal recessive inheritance.<sup id="cite_ref-:4_8-1" class="reference"><a href="#cite_note-:4-8">&#91;8&#93;</a></sup> In 2018, Yu-Wai-Man
et al compiled the clinical utility gene card for PCG which describes
situations for which gene testing may be useful. <sup id="cite_ref-:0_3-6" class="reference"><a href="#cite_note-:0-3">&#91;3&#93;</a></sup> Carriers of the CYP1B1 gene mutation and double null CYP1B1 alleles are, on average, more likely to have higher IOP and require more surgeries. <sup id="cite_ref-:14_6-2" class="reference"><a href="#cite_note-:14-6">&#91;6&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="General_Pathology">General Pathology</span></h2>
<p>Many theories have been developed,
yet the exact nature of anterior chamber development and the pathophysiology of
PCG has yet to be well-understood. It is generally agreed that elevated IOP
occurs due to poor aqueous outflow secondary to abnormal development of the
anterior chamber angle.&#160;
</p><p>The American Academy of Ophthalmology's  <a rel="nofollow" class="external text" href="https://www.aao.org/resident-course/pathology-atlas/">Pathology Atlas</a>  contains a virtual microscopy image of  <a rel="nofollow" class="external text" href="https://secure.aao.org/zoomify/CongenitalGlaucomaBuphthalmos.htm">Congenital Glaucoma</a> (not PCG, given presence of cataract). 
</p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span></h2>
<p>In 1955 and 1966, an imperforate
membrane covering the anterior chamber angle was described by Barkan and Worst (called Barkan membrane). <sup id="cite_ref-28" class="reference"><a href="#cite_note-28">&#91;28&#93;</a></sup><sup id="cite_ref-29" class="reference"><a href="#cite_note-29">&#91;29&#93;</a></sup>This structure has
not been confirmed histologically, and after numerous investigations, Barkan membrane is no longer thought to exist, and aqueous outflow obstruction
is thought to occur at the trabecular meshwork itself.<sup id="cite_ref-:4_8-2" class="reference"><a href="#cite_note-:4-8">&#91;8&#93;</a></sup><sup id="cite_ref-:5_30-0" class="reference"><a href="#cite_note-:5-30">&#91;30&#93;</a></sup> Furthermore, clinicopathologic studies with light microscopy, and scanning and transmission
electron microscopy, have shown abnormalities throughout the outflow pathway. A
high ciliary muscle insertion into the trabecular meshwork is often seen. Often
times, increased amounts of collagen in trabecular beam cores have been
demonstrated, with preserved trabecular spaces. And other times, elastic-type
fibers, fibrillary collagen and granular material or ground substance have been
seen in the trabecular spaces and the inner wall of Schlemm canal. The most
severe cases were associated with no visualization of the Schlemm canal and
collector channels. <sup id="cite_ref-31" class="reference"><a href="#cite_note-31">&#91;31&#93;</a></sup><sup id="cite_ref-32" class="reference"><a href="#cite_note-32">&#91;32&#93;</a></sup><sup id="cite_ref-33" class="reference"><a href="#cite_note-33">&#91;33&#93;</a></sup><sup id="cite_ref-:6_34-0" class="reference"><a href="#cite_note-:6-34">&#91;34&#93;</a></sup>
</p><p> Previously, it was thought that abnormal
cleavage and mesodermal tissue atrophy in anterior chamber angle development
was the root cause of PCG. Currently, the ruling hypothesis by Anderson begins in the third trimester when
normal angle development involves posterior sliding of the ciliary body and
peripheral iris (uveal tissues), away from the cornea and sclera. Anderson proposed
that excessive or premature accumulation of collagenous beams within the
trabecular meshwork inhibit posterior sliding of the ciliary body and
peripheral iris, leading to an anterior insertion of the iris root and ciliary
muscle, which can obstruct the trabecular meshwork, and narrow or completely
compress the Schlemm canal.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35">&#91;35&#93;</a></sup><sup id="cite_ref-36" class="reference"><a href="#cite_note-36">&#91;36&#93;</a></sup>  More recently, ultrasound
biomicroscopy and anterior segment optical coherence tomography have been used
to determine angle abnormalities in PCG patients.<sup id="cite_ref-:5_30-1" class="reference"><a href="#cite_note-:5-30">&#91;30&#93;</a></sup>
</p><p>Researchers have been correlating
neural crest cell (NCC) migration and differentiation with angle development
and the role of <i>CYP1B1</i> in ocular
fissure closure, which ultimately affects NCC migration. &#160;<sup id="cite_ref-37" class="reference"><a href="#cite_note-37">&#91;37&#93;</a></sup><sup id="cite_ref-38" class="reference"><a href="#cite_note-38">&#91;38&#93;</a></sup><sup id="cite_ref-:6_34-1" class="reference"><a href="#cite_note-:6-34">&#91;34&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Primary_prevention">Primary prevention</span></h2>
<p>There is no known way to prevent
PCG. Early detection and treatment are essential to
maximize visual potential.&#160;In the future, prenatal genetic screening may emerge as a preventative measure. It can be offered to parents in at-risk populations, such as those with family history or in consanguineous relationships in areas with higher PCG prevalence (Slovakia, Saudi Arabia, China, etc.). Parents with unborn children who test positively for mutations in CYP1B1 on genetic screening can be alerted about the potential need for urgent surgical management soon after birth. <sup id="cite_ref-:14_6-3" class="reference"><a href="#cite_note-:14-6">&#91;6&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Symptoms">Symptoms</span></h2>
<p>Patients with PCG experience one or
more of the "clinical triad" of symptoms including epiphora, photophobia and blepharospasm.
This triad of symptoms is classically associated with PCG due to the corneal
edema that results from the elevated IOP, and causes irritation. Reduced vision
can also occur from corneal edema/opacification or progressive myopia and/or
astigmatism. Amblyopia can further worsen vision.&#160; 
</p>
<h2><span class="mw-headline" id="Signs">Signs</span></h2>
<p>The main clinical signs of PCG include elevated IOP &gt;21 mmHg, corneal
edema and/or enlargement of the eye with buphthalmos, and Haab striae. The IOP at
presentation is usually between 30-40 mmHg, though it can be outside this
range. <sup id="cite_ref-39" class="reference"><a href="#cite_note-39">&#91;39&#93;</a></sup>
IOP in the low-20s mmHg is acceptable if the optic nerve is healthy and the
patient’s eye growth is within normal limits, but may not be if there are other
more severe signs of PCG. &#160; 
</p><p>With IOP in the 30-40s mmHg, the
cornea becomes cloudy due to diffuse and/or focal edema. As in adult eyes, the
endothelial cell layer cannot pump fluid out of the cornea in an eye with elevated IOP.
In young children however, there is the additional insult of corneal stretching
from the high IOP causing not only enlargement of the cornea, but Descemet
breaks, leading to “striae,” which are areas of bare stroma bordered by two
separated edges of Descemet membrane that become ridges due to deposition of
hyaline.<sup id="cite_ref-:4_8-3" class="reference"><a href="#cite_note-:4-8">&#91;8&#93;</a></sup> These are called
Haab striae and are associated with acute overlying focal corneal edema when
the IOP is high. They occur in about 25% of PCG eyes presenting at birth, and
more than 60% of PCG eyes identified at 6 months of age.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40">&#91;40&#93;</a></sup> There may be single
or multiple, and are oriented horizontally or obliquely. &#160;After normalization of IOP, corneal edema may
clear; however, Haab striae remain and may be associated with corneal scarring. The
poorly controlled cases of PCG may end up with dense stromal opacification even after
IOP is controlled. 
</p><p>A newborn’s cornea is typically
9.5-10.5 mm in diameter and increases to 10.0-11.5 mm by age 1.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41">&#91;41&#93;</a></sup> Any diameter above
12.0 mm before 1 year of age suggests an abnormality, especially if there is
asymmetry between the two eyes. If the diameter is greater than 13 mm at any
age, glaucoma suspicion should be high. Along with corneal stretching in the
setting of elevated IOP, there is stretching of the scleral wall and all
tissues within the eye leading to buphthalmos. Corneal enlargement stops around
age 3 years, while sclera can continue to stretch up to age 10 years of age.<sup id="cite_ref-:4_8-4" class="reference"><a href="#cite_note-:4-8">&#91;8&#93;</a></sup> 
</p><p>Other signs related to the eye
distension include abnormally deep anterior chamber, myopia (mainly due to
elongation and enlargement of the eye), astigmatism (from Haab striae and
corneal stretching), anisometropia (almost always present in unilateral PCG), and
optic nerve cupping. 
</p><p>The optic nerve cupping in very
young children may be seen solely due to optic canal stretching and posterior
bowing of the lamina cribrosa without a decrease in the neuroretinal rim.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42">&#91;42&#93;</a></sup><sup id="cite_ref-43" class="reference"><a href="#cite_note-43">&#91;43&#93;</a></sup> When the IOP is
normalized, there can be notable reversal of cupping. While cupping may
resolve, retinal nerve fiber layer damage, if present, is permanent. In
older children and those with advanced glaucoma, cupping occurs due to
neuroretinal rim tissue loss, especially at the vertical disk poles.<sup id="cite_ref-:4_8-5" class="reference"><a href="#cite_note-:4-8">&#91;8&#93;</a></sup>
</p><p>Any asymmetry between eyes in the
aforementioned signs should raise suspicion of glaucoma. Lastly, amblyopia,
either deprivation or both, may also be present with the other signs mentioned
above.
</p>
<h1><span class="mw-headline" id="Diagnosis">Diagnosis</span></h1>
<p>The diagnosis of PCG can often be made clinically, even without an accurate measurement of
IOP.  The hallmark of the disease, however, is an elevated
IOP and ocular stretching in the absence of other ocular and systemic conditions
that can cause glaucoma, such as Axenfeld-Reiger syndrome, aniridia, or
surgical removal of cataract in infancy (i.e. glaucoma following cataract surgery).&#160; 
</p>
<h2><span class="mw-headline" id="History">History</span></h2>
<p>PCG patients often present to the
physician’s office due to abnormal appearance of the eyes such as a cloudiness or
a blue tint to the eyes, or patient behavior such as eye rubbing or shying away
from light. While there may be tearing, there is no ocular discharge and usually no eye redness.
The patients are otherwise healthy. A positive family history is helpful but
often is not present since most cases are sporadic.&#160; 
</p>
<h2><span class="mw-headline" id="Physical_examination">Physical examination</span></h2>
<p>The physical exam follows the
standard ophthalmology exam for infants and young children, with special note
of signs related to ocular expansion due to the distensibility of the infant
eye. The vision assessment should specifically look for asymmetry in unilateral
cases and the presence of nystagmus and/or reduced fixation response in
bilateral cases.  
</p><p>The anterior segment exam should
specifically look at the corneal diameter. Measurement can be done in clinic by
holding a ruler in front of the patient’s eyes, however it may be much more
accurate under anesthesia if the patient is not cooperative in clinic. (Details
in “diagnostic testing.”)
</p><p>The cornea should also be examined
for clarity and the presence of one or multiple Haab striae (horizontal or
oblique breaks in Descemet membrane, described above). These may be obvious or subtle,
and sometimes can best be seen after dilation using retroillumination. Diffuse
corneal edema and/or focal corneal edema or opacification may obscure Haab
striae. The anterior segment exam should also look for anterior chamber depth
(deep in PCG), and structural abnormalities of the cornea, iris, and lens (no
frank abnormalities are seen in PCG, with the exception of mild iris changes in newborn-onset PCG).
</p><p>IOP can be reliably
measured in clinic with various devices (described below) if the child is calm,
sleeping or feeding. Distraction with toys or movies may help during
measurement. If the child is crying and uncooperative, then the IOP measurement
will likely be artificially elevated and exam under anesthesia may be required.
</p><p>&#160;Gonioscopy can be performed in the clinic
on older children, and must be done under anesthesia for younger patients.
Further description is in “diagnostic testing.” 
</p><p>After dilation, cycloplegic retinoscopy
should be performed to look for myopia, astigmatism, and any corneal
irregularity. The fundus exam should include a careful exam of the optic nerve
to look for asymmetric or large cupping and for any structural abnormalities. There
may be reversal of cupping after reduction in IOP in infants with glaucoma. <sup id="cite_ref-44" class="reference"><a href="#cite_note-44">&#91;44&#93;</a></sup>
</p><p>Axial length measurement (described
in "diagnostic testing") is also a key part of the physical exam in PCG. 
</p><p>The sequence and method the exam is
done in clinic may be modified to optimize obtaining IOP measurements when the
child is calm. For example, initial anterior segment exam may be done with a
penlight or direct ophthalmoscope instead of a portable slit lamp. IOP could be
the first part of the exam if the child is sleeping.&#160;
</p>
<h2><span class="mw-headline" id="Clinical_diagnosis">Clinical diagnosis</span></h2>
<p>The clinical diagnosis of PCG can be difficult, especially when a child does not cooperate with IOP measurement. If a reliable IOP measurement is elevated in the setting of other classic signs of ocular stretching (above),
then the diagnosis of glaucoma is made, and if no other ocular or systemic
developmental anomalies are seen, then PCG is the diagnosis. The presence of
Haab striae suggests congenital glaucoma, and if seen without ocular
developmental anomalies or systemic syndromes, then PCG is the diagnosis. If
IOP is normal with Haab striae, then one may have a case of spontaneously arrested PCG, which still needs to be followed over time for elevated IOP. &#160; 
</p>
<h2><span class="mw-headline" id="Diagnostic_procedures">Diagnostic procedures</span></h2>
<p>The main diagnostic test for PCG is the measurement of the IOP, which
should be done prior to instilling dilating drops. In a cooperative infant or young child,
this measurement can be obtained in the clinic setting with a Perkins
applanation tonometer, Tono-pen (a portable Mackay-Marg-type tonometer) and/or
Icare rebound tonometer. In older patients, standard Goldmann applanation
tonometry can be performed. A pneumotonometer may be useful to confirm
IOP during examination under anesthesia or in clinic if available, and may be
less influenced by corneal abnormalities. A Schiötz indentation tonometry is not recommended in these patients
due to under- or overestimation of IOP in childhood glaucoma.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45">&#91;45&#93;</a></sup><sup id="cite_ref-46" class="reference"><a href="#cite_note-46">&#91;46&#93;</a></sup>  
For the uncooperative patient, an examination under anesthesia should be
performed.  
</p><p>Of note, the Icare rebound tonometer
has decreased the need for examinations under anesthesia as it does not require
a topical anesthetic.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47">&#91;47&#93;</a></sup> &#160;Two models available in the United States
(Icare TAO1i and Icare ic100) require the patient to be upright, while the
newest model, recently approved in the US (Icare ic200), allows measurement in a supine patient. The IOP measured by
Icare in cooperative, awake children with known or suspected glauacoma, has been shown to be within 3 mmHg of IOP obtained by Goldmann applanation tonometry in 63% and is higher than measured by Goldmann applanation tonometry in 75% of
children.<sup id="cite_ref-48" class="reference"><a href="#cite_note-48">&#91;48&#93;</a></sup> By contrast, Icare tonometry may under-measure the IOP compared to Tono-pen readings in the setting of corneal edema.<sup id="cite_ref-49" class="reference"><a href="#cite_note-49">&#91;49&#93;</a></sup> 
</p><p>Because anesthetic agents variably
alter the IOP, with most lowering IOP,  measurements should
be obtained as soon as possible after induction of anesthesia and before
intubation. If the IOP is actually elevated, it often remains greater than 20
mmHg under anesthesia, which suggests glaucoma. &#160;The normal IOP is lower in
infants and young children than adults. A newborn has an average IOP of 10-12 mm Hg, increasing to 14 mm Hg by age 7 or 8 years of age. An
asymmetric measurement or an elevated IOP measurement in the presence of other
clinical signs helps make the diagnosis of glaucoma. 
</p><p>Corneal diameter measurement is
another key diagnostic procedure for PCG. Some providers check horizontal
diameters only, while some check horizontal and vertical diameters. If there is
pannus or scarring obscuring the limbus, the measurement may not be accurate. In
the office a millimeter ruler can be placed above the eyes and if the child is
not cooperative, a close-up digital photograph can be taken with the ruler in
place, and a measurement can be made from the photo. This is most amenable to
horizontal corneal diameter measurement. While under anesthesia, calipers with
the tips placed at the limbus 180 degrees apart are used across the widest diameter, and then measured with a graduated ruler to check the measurement. Ideally, the measurement can be
estimated to the nearest 0.25 mm.<sup id="cite_ref-:1_2-4" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> 
</p><p>Examination for Haab striae is done with
an oblique slit beam with a portable slit lamp if the patient is younger or
under anesthesia, or on a regular slit lamp in the clinic if the patient is
older. Retroillumination can also be used to identify Haab striae. . In older patients with treated PCG, corneal endothelial protuberances and hyperproliferation of the Descemet membrane/pre-Descemet’s layer complex have been demonstrated with anterior segment OCT (ASOCT). These may demarcate areas in which the edges of the Descemet membrane have re-approximated during the healing process.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50">&#91;50&#93;</a></sup> 
</p><p>If a view through the cornea allows
it, gonioscopy is done in clinic if tolerated, ideally a Sussman (or similar) indirect gonioscopy lens
as it fits easily between a young child’s small palpebral fissure. Using a gonioscopy lens without a handle
may be easier as it allows the examiner to hold open the eyelids while placing
the lens. More commonly, for initial diagnosis of PCG, gonioscopy is performed under under
anesthesia with a Koeppe or similar direct gonioscopy lens and portable slit lamp. There
are different sized Koeppe lenses to fit different corneal diameters. The
Koeppe lens is best handled with a glove to avoid fingerprint smudges. The
Koeppe lens cup is filled with balanced salt solution and placed quickly on the
eye or placed on the eye and tilted with one edge abutting the sclera while
filling the space between the lens and eye with solution. Then a binocular
microscope such as the portable slit lamp is angled towards the angle of
interest and the lens can be shifted slightly toward the angle to optimize the
view. 
</p><p>Gonioscopy in these cases helps guide surgical planning in cases of PCG, and may also identify other angle abnormalities which might identify other secondary glaucoma types, for example Axenfeld-Rieger anomaly (many irido-corneal attachments with anteriorly placed Schwalbe line). Infants
with PCG usually do not have a visible scleral spur because the peripheral iris inserts
into the trabecular meshwork (in contrast to normal infants whose peripheral
iris and ciliary body have recessed to the scleral spur or posterior to it). There
may also be scalloped edges of the peripheral iris and pale peripheral iris
stroma in front of the angle causing a “morning mist” appearance. If there are
peripheral anterior synechiae, posterior embryotoxon, or other abnormalities,
then the diagnosis is unlikely PCG. Gonioscopy photographs can be taken by instilling
the eye with coupling gel and angling the camera lens (i.e. RetCam)
obliquely toward the angle of interest and adjusting the focus until the angle
comes into clear view. 
</p><p>Axial length is measured with A-scan
ultrasonography, ideally using the immersion and not contact method, either in
clinic or under anesthesia. It is best done under anesthesia, during baseline examination to
determine if the axial length is greater than normal for the patient’s age, and
repeated approximately every 3-4 months to assess if the growth rate is greater
than average. Of note, measuring axial length itself is not an indication for examination under anesthesia if a patient is otherwise doing well, and can be performed at intervals when examination under anesthesia is needed for clinical management. Sampaolesi and Kiskis provided linear regressions from data of
normal children. Sampaolesi used immersion A-scans and found the normal axial
length for a one-month-old lies between 17.25 mm (5<sup>th</sup> percentile)
and 20.25 mm (95<sup>th</sup> percentile). Sampaolesi also recommended that
axial length be measured after dilation with cycloplegic drops.<sup id="cite_ref-:1_2-5" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup><sup id="cite_ref-:7_51-0" class="reference"><a href="#cite_note-:7-51">&#91;51&#93;</a></sup> 
</p><p>Optic nerve evaluation is performed with
either indirect or direct ophthalmoloscopy with attention to the cup-to-disc
ratio. In the setting of a small pupil, a magnified view of the nerve can be
obtained by using a direct ophthalmoscope through a Koeppe gonioscopy lens on the eye. Fundus
photography is also recommended for comparisons between serial examinations. B-scan
ultrasonography is recommended if the cornea does not allow fundus examination
to rule out posterior disease. Severe optic nerve cupping may sometimes be noted on the
posterior B-scan. 
</p><p>Pachymetry is used to measure
central corneal thickness. The central cornea may be thicker due to corneal edema, and has also
shown to be thinner in PCG patients without corneal edema, likely due to stretching
of their tissues. <sup id="cite_ref-52" class="reference"><a href="#cite_note-52">&#91;52&#93;</a></sup> Other small studies have shown either no significant difference in central corneal thickness between normal eyes and eyes treated for PCG, or the central corneal thickness was thicker in eyes treated for PCG than in normal eyes.<sup id="cite_ref-:10_53-0" class="reference"><a href="#cite_note-:10-53">&#91;53&#93;</a></sup> <sup id="cite_ref-:11_54-0" class="reference"><a href="#cite_note-:11-54">&#91;54&#93;</a></sup> Corneal hysteresis and corneal resistance factor have been found to be lower in eyes with PCG compared to normal eyes.<sup id="cite_ref-:10_53-1" class="reference"><a href="#cite_note-:10-53">&#91;53&#93;</a></sup><sup id="cite_ref-:11_54-1" class="reference"><a href="#cite_note-:11-54">&#91;54&#93;</a></sup>
</p><p>Perimetry can be attempted starting
around age 7-8 years of age if the patient does not have nystagmus, cognitive
impairment or severe vision loss. Quicker testing algorithms such as SITA-FAST may allow children to
perform more reliably.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55">&#91;55&#93;</a></sup> Goldman perimetry can be very helpful in young children.  
</p><p>Standard tabletop optical coherence
tomography (OCT) can be considered once a child can be examined at the regular
slit lamp to evaluate the retinal nerve fiber layer and ganglion cell layer. It
may be helpful especially if the child cannot perform perimetry. While devices
currently do not carry normative data for children, studies have collected data
on normal children. <sup id="cite_ref-56" class="reference"><a href="#cite_note-56">&#91;56&#93;</a></sup><sup id="cite_ref-57" class="reference"><a href="#cite_note-57">&#91;57&#93;</a></sup><sup id="cite_ref-58" class="reference"><a href="#cite_note-58">&#91;58&#93;</a></sup><sup id="cite_ref-59" class="reference"><a href="#cite_note-59">&#91;59&#93;</a></sup> Handheld and mounted
spectral-domain OCT devices are emerging technologies that can be used during
examination under anesthesia.<sup id="cite_ref-60" class="reference"><a href="#cite_note-60">&#91;60&#93;</a></sup><sup id="cite_ref-61" class="reference"><a href="#cite_note-61">&#91;61&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Laboratory_test">Laboratory test</span></h2>
<p>Ophthalmology
providers may work with genetics team members to send for genetic testing if
available.&#160; 
</p>
<h2><span class="mw-headline" id="Differential_diagnosis">Differential diagnosis</span></h2>
<p>The differential diagnosis depends
on the presenting symptom(s) and is considered when key features of PCG,
such as elevated IOP and optic nerve cupping, are absent.  
</p><p>For epiphora, the differential
diagnosis includes nasolacrimal duct obstruction, conjunctivitis, corneal
abrasion, keratitis, and uveitis. Photophobia and blepharospasm are unlikely
with nasolacrimal duct obstruction and conjunctivitis, however, may be seen
with corneal abrasion/injury, keratitis, or uveitis. 
</p><p>For corneal clouding or
opacification, the differential diagnosis includes birth trauma generally involving
forceps causing Descemet tears that are vertical or oblique (unlike Haab striae
which are usually more horizontal or curvilinear), corneal dystrophies (such as congenital
hereditary endothelial dystrophy or posterior polymorphous dystrophy), congenital
or developmental abnormalities (such as sclerocornea, Peters anomaly), keratitis
(from intrauterine infection or inflammation such as herpetic infection,
congenital syphilis, and maternal rubella, and Riley-Day syndrome), storage
diseases, inborn errors of metabolism (such as mucopolysaccharidoses,
mucolipidoses, cystinosis and oculocerebrorenal (Lowe) syndrome), and
choristomas. 
</p><p>For corneal enlargement, the
differential diagnosis includes high axial myopia and megalocornea. Megalocornea
is an inherited disorder in which infants have clear corneas with diameters
&gt; 14 mm, deep anterior chambers, and iridodonesis. There have been reports
within one family of megalocornea coexistent with congenital glaucoma.<sup id="cite_ref-62" class="reference"><a href="#cite_note-62">&#91;62&#93;</a></sup> 
</p><p>For optic nerve cupping, the
differential diagnosis includes physiologic cupping, optic nerve coloboma,
optic nerve atrophy, optic nerve hypoplasia, and an optic nerve malformation. 
</p><p>Note many of the above diagnoses may
coexist with congenital glaucoma, however it would not be considered primary
congenital glaucoma, but under the category of secondary childhood glaucoma.&#160;
</p>
<h1><span class="mw-headline" id="Management">Management</span></h1>
<p>The management of PCG is directed toward lowering and controlling the IOP and treating the secondary complications such as refractive change and
amblyopia that develop during the course of the disease.&#160; 
</p>
<h2><span class="mw-headline" id="General_treatment">General treatment</span></h2>
<p>The mainstay of treatment is angle
surgery, either goniotomy or trabeculotomy, to lower IOP by
improving aqueous outflow. If angle surgery is not successful, trabeculectomy
enhanced with mitomycin C or glaucoma implant surgery with a Molteno, Baerveldt,
or Ahmed implant can be performed. In refractory cases, cycloablation can be
performed using an Nd:YAG laser, diode laser, or cryotherapy, with diode laser being the most widely used device. Medical therapy, either topically or orally, is typically
used as a temporizing measure prior to surgery and to help decrease corneal
clouding to facilitate goniotomy, and to supplement IOP control
after surgery. &#160;In managing secondary congenital glaucoma, medical therapy is the first-line treatment. <sup id="cite_ref-63" class="reference"><a href="#cite_note-63">&#91;63&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Medical_therapy">Medical therapy</span></h2>
<p><a href="/Medical_Management_for_Primary_Open_Angle_Glaucoma" class="mw-redirect" title="Medical Management for Primary Open Angle Glaucoma">Medical therapy</a> for PCG is typically used as an adjunct to surgery.
Most medications in the United States have not been approved for children,
however many studies have been performed that inform practitioners on their safety
and efficacy in children.  Timolol is the first choice in pediatric glaucoma. In cases with insufficient reduction of the intraocular pressure (IOP), the combination of timolol once a day and dorzolamide twice a day brings about a good control of the IOP. Both medications are effective and well tolerated. The alpha2-agonists have more and potentially serious adverse effects in children and are contraindicated for children younger than 2 years of age. Latanoprost tends to be less effective in lowering IOP in children than in adults.<sup id="cite_ref-64" class="reference"><a href="#cite_note-64">&#91;64&#93;</a></sup>  
</p><p><b><u>Beta-blockers (beta-adrenergic antagonists):</u></b> <b></b>Topical beta-blockers play a large role in PCG treatment and include timolol (non-selective beta-1 and beta-2 blocker, concentrations of
0.1% available in some countries, 0.25% and 0.5% solutions, and 0.25% and 0.5%
gel-forming solution), and betaxolol (selective beta-1-blocker, concentrations
of 0.25% and 0.5% solutions). Given potentially high plasma levels of the
medication from topical instillation in small children, the lowest
concentration available should be initiated first. The solution drops are
approved for BID dosing though may be just as effective dosed once in the
morning. The gel-forming solutions are approved for once daily dosing.
Beta-blockers typically reduce IOP by 20-30%. Side effects are mainly systemic and include
respiratory distress, caused by apnea or bronchospasm (which may present as
coughing instead of wheezing), and bradycardia. <b>Beta-blockers should be avoided in patients with bradycardia, second- or third-degree atrioventricular block, and active asthma or “reactive airways.”</b> Betaxolol may be less likely to cause
pulmonary distress (e.g. asthma attacks) and cardiac side effects.<sup id="cite_ref-65" class="reference"><a href="#cite_note-65">&#91;65&#93;</a></sup>
</p><p><b><u>Carbonic anhydrase inhibitors:</u></b> Oral
carbonic anhydrase inhibitors include acetazolamide (Diamox, dose 10-20
mg/kg/day divided into 3 or 4 doses) and methazolamide (Neptazane, dose &lt; 2
mg/kg/day, divided into 2 doses<sup id="cite_ref-:1_2-6" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup><sup id="cite_ref-66" class="reference"><a href="#cite_note-66">&#91;66&#93;</a></sup>). Acetazolamide can be prepared in a flavored
syrup (have the pharmacist crush the tablets and suspend the powder in syrup)
with a concentration of 50 mg/ml for ease of use. Children can also take the
tablet crushed in applesauce or something similar. It reduces the IOP about
20-35%. Side effects occur in &gt;40% of patients and include lethargy,
decreased appetite, weight loss, gastrointestinal discomfort, diarrhea and
metabolic acidosis. Topical carbonic anhydrase inhibitors include dorzolamide
2% (Trusopt) and brinzolamide 1% (Azopt) drops twice a day (BID) or three times a day (TID). These medications
may produce less reduction in IOP (about 25%) than oral
carbonic anhydrase inhibitors, but also appear to have fewer systemic side effects.
Rarely, side effects can occur, particularly in premature infants, such as
metabolic acidosis.<sup id="cite_ref-67" class="reference"><a href="#cite_note-67">&#91;67&#93;</a></sup> Topical carbonic anhydrase inhibitors ideally should be avoided or used as a later option in the setting of compromised corneas, especially of a corneal transplant.<sup id="cite_ref-:1_2-7" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> 
</p><p><b><u>Combination beta-blocker/carbonic anhydrase inhibitor:</u></b> Timolol 0.5%-dorzolamide 2% (Cosopt) drop BID has been shown to be effective in reducing IOP in children requiring
more than one topical medication. It is approved for BID dosing, but cautious
use in young children is warranted due to the higher concentration of timolol. 
</p><p><b><u>Adrenergic agonists</u></b> (avoid or use with caution in
children younger than age 6 years or weight less than 20 kg): Apraclonidine 0.5% (Iopidine) and brimonidine (Alphagan, Alphagan P, 0.1%,
0.15%, 0.2%) are alpha-2 selective agonists and are dosed BID to TID. Their
effectiveness has not been studied specifically for PCG. The side effects in
children limit their use. Due to being highly lipophilic, brimonidine passes
through the blood-brain barrier potentially causing severe sleepiness, respiratory
depression, apnea and coma, especially in neonates and infants, thus <b>it is strictly</b>
<b>contraindicated in patients 2 years old or younger</b>.<b> </b>It may also cause
bradycardia, hypotension, hypotonia, and hypothermia. Apraclonidine is more
hydrophilic which reduces its blood-brain barrier penetration and thus has
fewer central nervous system side effects than brimonidine. It must still be used with caution and
is best used for short- or intermediate-term IOP lowering. Tachyphylaxis and
ocular allergy limit its effectiveness long-term. 
</p><p><b><u>Combination beta-blocker/alpha-2 adrenergic agonists:</u></b> Timolol 0.5%-brimonidine 0.2% (Combigan) must not be prescribed to children if there is a contraindication to the individual
components. 
</p><p><b><u>Prostaglandin analogs:</u></b> Latanoprost
0.005% (Xalatan), travoprost 0.004% (Travatan), bimatoprost 0.01% (Lumigan),
and tafluprost (Zioptan, preservative-free) are dosed nightly. Latanoprost
reduces the IOP in PCG 15-20%.<sup id="cite_ref-68" class="reference"><a href="#cite_note-68">&#91;68&#93;</a></sup> 
While the FDA has not approved prostaglandin analogs in children, Europe has
approved latanoprost for children. Side effects mainly include lash growth,
conjunctival injection, and less commonly iris pigmentation alteration,
allergy, uveitis and periocular hyperpigmentation. Side effects seem more
prominent with use of travoprost and bimatoprost and less with latanoprost.
Long-term side effects are still unknown in children. Prostaglandin-related periorbitopathy has been described in children.<sup id="cite_ref-69" class="reference"><a href="#cite_note-69">&#91;69&#93;</a></sup> This class of medication is relatively contraindicated when active inflammation or uveitis is present.  
</p><p><b><u>Combination beta-blocker/prostaglandin analog:</u></b> Available in countries outside the United States. 
</p><p><b><u>Miotic agents:</u></b> These do not play
much of a role in PCG likely due to their immature angle anatomy and high
ciliary muscle insertion. They include echothiophate, phospholine iodide
(irreversible cholinesterase and pseudocholinesterase inhibitors) and
pilocarpine (direct parasympathomimetic). Miotic are useful perioperatively for
angle surgery. Pilocarpine (0.5-6%, most common 1-2%) is dosed once to four
times a day, usually 2-3 times a day after angle surgery. Side effects include
miosis, decreased heart rate, apnea, sweating, and hypersalivation, and
theoretically may induce cataract and retinal detachment. 
</p><p><b><u>Modified prostaglandin analogs and rho-associated protein kinase inhibitors: </u></b>Latanoprostene bunod (Vyzulta) and netarsudil (Rhopressa) have not been studied
in patients younger than 18 years of age.&#160;
</p><p>Providers
can start with a either a carbonic anhydrase inhibitor, beta-blocker or
prostaglandin analog, or a combination, and progressively add another
medication class, keeping in mind medications are generally a
temporizing measure prior to surgery. If prescribed before initial surgery, medications should not be used without fairly frequent follow-up, and ideally surgery performed within 2 weeks of PCG diagnosis. Early discussion preparing family and caregivers for surgery is necessary.
Medications should be continued until surgery, and may help maximize corneal
clearing by reducing the IOP. After surgery, medications may still be needed as
an adjunct and family and caregivers should be made aware of this. Compliance
may be an issue when the medication regimen becomes complex and should be
addressed. PCG requires lifelong serial measurements of IOP, corneal diameter, axial length, refractive error, and
optic nerve cupping. If an adequate assessment is not possible in the
outpatient clinic, an examination under anesthesia should be performed.&#160;
</p>
<h2><span class="mw-headline" id="Surgery">Surgery</span></h2>
<p>There are four major surgical
options for PCG; however once the diagnosis of PCG is
established, angle surgery is the first procedure of choice to incise/open the
trabecular meshwork with the hope of allowing aqueous flow from the anterior
chamber directly into Schlemm canal. It is generally agreed that angle surgery is
most successful in infantile-onset PCG, and less so in newborn or late-recognized
PCG. Goniotomy is preferred by some surgeons when the cornea is clear enough to permit
visualization of anterior segment structures (although some prefer trabeculotomy regardless of the corneal clarity, see below). An incision is made across the trabecular
meshwork under direct gonioscopic visualization using a goniotomy knife (Swan
knife, needle-knife, disposable 25-gauge needle on a syringe) and surgical
goniotomy lens (i.e. Barkan or other goniotomy lens). Traditionally, it is first performed nasally,
however modifications can be made to complete it temporally as well at one surgical session. If a
surgeon is comfortable with devices and modified techniques such as using the
Kahook dual blade, Trabectome, gonioscopy-assisted transluminal trabeculotomy
with suture or lighted microcatheter, or Omni, these devices can be used safely
to perform a goniotomy in children, however it is not recommended to use these
devices in a pediatric eye prior to extensive experience in an adult eye. There
is no data to suggest these modified techniques do better than traditional
goniotomy or trabeculotomy. Complications include hyphema, anterior chamber
shallowing, peripheral anterior synechiae, and rarely, iridodialysis,
cyclodialysis, cataract, scleral perforation, epithelial ingrowth, and retinal
detachment.<sup id="cite_ref-70" class="reference"><a href="#cite_note-70">&#91;70&#93;</a></sup><sup id="cite_ref-:1_2-8" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup>  
</p><p>When the cornea is not clear enough
to permit visualization of the angle, or if preferred due to technical factors or surgeon experience or preference, trabeculotomy ab externo
(“trabeculotomy”) is the procedure of choice. Access to Schlemm canal is
obtained externally via a partial scleral flap to allow cannulation of Schlemm canal. The older technique opened ~90
degrees of Schlemm canal with a curved rigid pronged probe called a
trabeculotome, which can then be rotated gently into the anterior chamber to incise
through the trabecular meshwork. A trabeculotome curved in the opposite
direction can then be used to cannulate another 90 degrees of Schlemm canal and
complete 180 degrees of trabeculotomy. Alternatively, and preferred by many angle surgeons at this time, a 6-0 polypropylene
(Prolene) suture or an illuminated microcatheter can be threaded into the
entire Schlemm canal and pulled across the anterior chamber to complete a
360-degree trabeculotomy. Complications include hyphema, unintentional
filtering blebs, choroidal detachment, cyclodialysis, iridodialysis, lens
injury, and infection. 
</p><p>Traditional goniotomy and
trabeculotomy ab externo (incising 2 quadrants) have success rates ranging for
goniotomy 30-65% and for trabeculotomy 40-80%, with success reported as low as 10% to as
high as 94%.<sup id="cite_ref-71" class="reference"><a href="#cite_note-71">&#91;71&#93;</a></sup><sup id="cite_ref-:1_2-9" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> 
</p><p>Combined trabeculotomy and
trabeculectomy (CTT) can be performed if Schlemm canal could not be cannulated or
prior trabeculotomy failed, in which a trabeculectomy is added to the
trabeculotomy by removing a block of tissue in the scleral flap bed followed by
a surgical iridectomy as done in regular trabeculectomy. Mitomycin C (MMC) may
be used with care. CTT can be an initial surgical procedure, especially in
Indian and Middle Eastern patients.<sup id="cite_ref-72" class="reference"><a href="#cite_note-72">&#91;72&#93;</a></sup><sup id="cite_ref-73" class="reference"><a href="#cite_note-73">&#91;73&#93;</a></sup> 
</p><p>Filtering surgery is considered when
one or more angle surgeries have failed and includes traditional trabeculectomy
with or without MMC, and glaucoma drainage device implantation. Trabeculectomy may be best done using techniques of the Moorfields Safer Surgery System, including
fornix-based conjunctival flaps, small radial cuts, MMC under the sclera flap
and subconjunctival tissue with wider spread to enhance posterior aqueous flow
and reduce bleb-related complications. Use of an anterior chamber maintainer in
all cases and releasable sutures are also recommended.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74">&#91;74&#93;</a></sup><sup id="cite_ref-75" class="reference"><a href="#cite_note-75">&#91;75&#93;</a></sup><sup id="cite_ref-76" class="reference"><a href="#cite_note-76">&#91;76&#93;</a></sup>  EX-PRESS mini
glaucoma shunts are not used commonly in PCG as safety and efficacy have not
been established long-term in young children. Severe complications of
trabeculectomy include vitreous loss, ectasia, scleral collapse, retinal
detachment, and phthisis. The child is also at lifelong risk of complications and
infection including bleb leak, wound rupture, blebitis, and endophthalmitis. 
</p><p>Reported success rates for trabeculectomy performed for PCG range between 50-87%.<sup id="cite_ref-:1_2-10" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> The risk of failure is 5.6 times higher in
patients age 1 year or less.<sup id="cite_ref-77" class="reference"><a href="#cite_note-77">&#91;77&#93;</a></sup> 
The higher risk of failure in advanced PCG young patients is due to
buphthalmos, lack of scleral rigidity, and highly active healing and scarring. 
</p><p>When trabeculectomy fails or is not
a desirable option, then the other filtering option with glaucoma drainage
device (GDD) surgery or cyclodestructive procedures are the next surgical
choices. All models of GDDs (Molteno, Baerveldt, and Ahmed valve) can be used
in PCG patients, and GDDs can be implanted safely in neonates with attention to
eye and implant parameters. Generally, it is advisable to use a fornix incision with conjunctival and Tenon capsule incision 8 mm posterior to the
limbus, and double-layer closure with running 8-0 polyglactin (Vicryl) suture
on a vascular needle. The flexible implants (Baerveldt and Ahmed) can be
trimmed posteriorly so as to prevent plate-optic nerve touch. The amount to
trim can be calculated with the online Freedman-Margeta GDD calculator (http://people.duke.edu/~freed003/GDDCalculator/).<sup id="cite_ref-78" class="reference"><a href="#cite_note-78">&#91;78&#93;</a></sup> Some surgeons place the first tube inferior nasal to preserve conjunctiva
superiorly for possible trabeculectomy when the patient is older, however
others prefer superior temporal placement of the first tube, for better
efficacy, and are able to perform successful trabeculectomy superior nasal at a
future time. Complications from GDDs are many and include those of
trabeculectomy plus cornea-tube touch, tube erosion through the conjunctiva or
cornea, implant migration, and cataract. Infection rates are low.<sup id="cite_ref-79" class="reference"><a href="#cite_note-79">&#91;79&#93;</a></sup> The Ahmed valve may additionally fail due to fibrovascular ingrowth into the valve chamber.<sup id="cite_ref-80" class="reference"><a href="#cite_note-80">&#91;80&#93;</a></sup>
</p><p>Success rates vary widely for PCG
and childhood glaucoma. For the Molteno, the range is 56-95%, with slightly
higher success with the double-plate implant compared to the one-plate implant.<sup id="cite_ref-81" class="reference"><a href="#cite_note-81">&#91;81&#93;</a></sup><sup id="cite_ref-82" class="reference"><a href="#cite_note-82">&#91;82&#93;</a></sup> The Baerveldt
success rates range from 80-95% at 12 months, decreasing to &lt; 50%&#160; by 60 months.<sup id="cite_ref-83" class="reference"><a href="#cite_note-83">&#91;83&#93;</a></sup><sup id="cite_ref-84" class="reference"><a href="#cite_note-84">&#91;84&#93;</a></sup>  The Ahmed glaucoma
valve has about a 55% success rate at 5 years.<sup id="cite_ref-85" class="reference"><a href="#cite_note-85">&#91;85&#93;</a></sup><sup id="cite_ref-86" class="reference"><a href="#cite_note-86">&#91;86&#93;</a></sup> 
</p><p>Cyclodestructive procedures are
useful tools in managing refractory PCG after all other options have been
tried, to reduce aqueous production. Results are unpredictable and
complications exist. Laser cyclophotocoagulation (CPC) has largely replaced
cyclocryotherapy, and diode laser is preferred to Nd:YAG laser due to decreased
adverse events such as sympathetic ophthalmia. Transscleral and endoscopic
application of laser are both options, with endoscopic preferred if the eye
anatomy allows. Transscleral Micropulse-CPC may have less severe complications
than traditional transscleral CPC and be as effective in children,<sup id="cite_ref-87" class="reference"><a href="#cite_note-87">&#91;87&#93;</a></sup> though further research is needed. The limbal anatomy
may be distorted and blind application of transscleral CPC may be better guided
with ultrasound biomicroscopy.<sup id="cite_ref-88" class="reference"><a href="#cite_note-88">&#91;88&#93;</a></sup> A general rule of
thumb for all cyclodestructive procedures is to maintain 1-2 clock hours of
untouched ciliary processes, even after repeated sessions, thus careful
documentation of treated areas is recommended. Rare complications include
hypotony, retinal detachment, visual loss, and phthisis. 
</p><p>Success for transscleral CPC ranges
from 30-79% with retreatment in ~70% of patients, and has been comparable to
implanting a second GDD in children. <sup id="cite_ref-89" class="reference"><a href="#cite_note-89">&#91;89&#93;</a></sup><sup id="cite_ref-:8_90-0" class="reference"><a href="#cite_note-:8-90">&#91;90&#93;</a></sup><sup id="cite_ref-:9_91-0" class="reference"><a href="#cite_note-:9-91">&#91;91&#93;</a></sup><sup id="cite_ref-92" class="reference"><a href="#cite_note-92">&#91;92&#93;</a></sup>  Endoscopic
cyclophotocoagulation (ECP) has been reported to be 64% successful at 1 year,
and 16% by 5 years, with sequential ECP bringing the rate up to 81% at 1 year,
and 34% at 5 years.<sup id="cite_ref-93" class="reference"><a href="#cite_note-93">&#91;93&#93;</a></sup><sup id="cite_ref-94" class="reference"><a href="#cite_note-94">&#91;94&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Surgical_follow_up">Surgical follow up</span></h2>
<p>In the short term, these patients
require frequent follow up to follow response to treatment and monitor for hypotony, infection, and excessive
inflammation. For young patients, or patients with less than 2 years of IOP
control, follow-up is recommended at least every 3-4 months. Regular life-long
follow-up is needed (at least every 6 months) because even if long-term IOP
control from a surgical intervention is achieved, asymptomatic relapse can
occur at any time and will need to be managed with medications or further
surgery. Additionally, vision-threatening complications may occur at any time,
especially after filtering surgeries.  
</p><p>Of note, GDD patency can be assessed
with B-scan ultrasonography in the clinic.<sup id="cite_ref-95" class="reference"><a href="#cite_note-95">&#91;95&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Complications">Complications</span></h2>
<p>Complications for surgeries are
described in the “Surgery” section.  
</p><p>Untreated IOP or
delayed treatment in an infant eye may lead to severe complications and
significant visual impairment in addition to permanent optic nerve damage and
glaucomatous visual field defects. High IOP causes corneal edema and
corneal stretching with development of Haab striae. With prolonged corneal
edema, both diffuse and focal overlying Haab striae, the cornea can become
permanently opacified. Buphthalmos with axial elongation, and Haab striae cause
abnormally high refractive errors including myopia and astigmatism, that can
impair vision both by blurring vision and causing refractive amblyopia, which
can be exacerbated by anisometropia in unilateral cases. In severe buphthalmos,
with continued stretching, the lens could dislocate, and risk of retinal complications increases (i.e. lacquer cracks and retinal detachments). Overcoming these
complications can be difficult in severe cases. Corneal transplantation for
corneal opacification is avoided if possible due to high risk of failure and
complications in young children.&#160;
</p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span></h2>
<p>The prognosis for untreated PCG is almost always buphthalmos and blindness, except in the
rare case of spontaneously arrested PCG. When PCG is being managed, the
prognosis seems to depend on the age of onset, which depends on the severity of
the angle anomaly. Eyes with more severe angle abnormalities tend to present earlier and to have worse prognosis compared with infantile-onset cases.<sup id="cite_ref-:1_2-11" class="reference"><a href="#cite_note-:1-2">&#91;2&#93;</a></sup> Interestingly, angle surgery is most successful in patients presenting between 2 months and 1 year
of age (infantile-onset PCG) with 90% success, and less in newborn or
late-recognized PCG with &lt;50% success. In general, IOP control is obtained in
greater than 80% of patients.<sup id="cite_ref-96" class="reference"><a href="#cite_note-96">&#91;96&#93;</a></sup> 
Visual prognosis depends on the degree of corneal scarring, anisometropia,
refractive or deprivation amblyopia, and optic nerve damage. With maximal
glaucoma and amblyopia therapy, one study found median VA of 20/60.<sup id="cite_ref-:13_5-1" class="reference"><a href="#cite_note-:13-5">&#91;5&#93;</a></sup><sup id="cite_ref-:12_4-1" class="reference"><a href="#cite_note-:12-4">&#91;4&#93;</a></sup>  Strict attention to
maximizing IOP control, correction of refractive errors and treatment of
amblyopia is crucial. Early referral to visual assistance programs offered
through the county or school system can be beneficial.  
</p><p>Consideration must also be given to
the burden on caregivers, whose actions likely will affect the patient’s
prognosis. Recent studies have highlighted that one-third of PCG caregivers
could have moderate to severe depression, and quality of life is poorer for the
caregiver if the patient is older and has had the disease longer.<sup id="cite_ref-97" class="reference"><a href="#cite_note-97">&#91;97&#93;</a></sup> 
</p>
<h1><span class="mw-headline" id="Additional_Resources">Additional Resources</span></h1>
<ul><li>AAO, Basic and Clinical Science Course, Section 6: Pediatric Ophthalmology and Strabismus, 2019-2020, p 277-284.</li>
<li>Ho, C L, Walton, D S. PCG: 2004 Update. JPOS 2004; 41:271-288.</li>
<li>Weinreb R.N., Grajewski A.L., Papadopoulos M., Grigg J.,Freedman S.F. <i>Childhood glaucoma: the 9th consensus report of the World Glaucoma Association. </i>Netherlands: Kugler Publications, 2013.</li>
<li><a rel="nofollow" class="external text" href="https://aapos.org/browse/glossary/entry?GlossaryKey=e9951c95-e710-444c-8ad8-1b1a4d860d97">Patient Information: Glaucoma for Children by the American Association of Pediatric Ophthalmology and Strabismus</a></li>
<li>American Academy of Ophthalmology. Congenital glaucoma, cloudy corneas. https://www.aao.org/image/congenital-glaucoma-cloudy-corneas-2 Accessed July 01, 2019.</li></ul>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><a href="#cite_ref-1">↑</a></span> <span class="reference-text">American Academy of Ophthalmology. Congenital glaucoma, cloudy corneas. <a rel="nofollow" class="external free" href="https://www.aao.org/image/congenital-glaucoma-cloudy-corneas-2">https://www.aao.org/image/congenital-glaucoma-cloudy-corneas-2</a> Accessed July 01, 2019.</span>
</li>
<li id="cite_note-:1-2"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:1_2-0">2.00</a></sup> <sup><a href="#cite_ref-:1_2-1">2.01</a></sup> <sup><a href="#cite_ref-:1_2-2">2.02</a></sup> <sup><a href="#cite_ref-:1_2-3">2.03</a></sup> <sup><a href="#cite_ref-:1_2-4">2.04</a></sup> <sup><a href="#cite_ref-:1_2-5">2.05</a></sup> <sup><a href="#cite_ref-:1_2-6">2.06</a></sup> <sup><a href="#cite_ref-:1_2-7">2.07</a></sup> <sup><a href="#cite_ref-:1_2-8">2.08</a></sup> <sup><a href="#cite_ref-:1_2-9">2.09</a></sup> <sup><a href="#cite_ref-:1_2-10">2.10</a></sup> <sup><a href="#cite_ref-:1_2-11">2.11</a></sup></span> <span class="reference-text">Weinreb R.N., Grajewski A.L., Papadopoulos M., Grigg J.,Freedman S.F. <i>Childhood glaucoma: the 9th consensus report of the World Glaucoma Association. </i>Netherlands: Kugler Publications, 2013.</span>
</li>
<li id="cite_note-:0-3"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:0_3-0">3.0</a></sup> <sup><a href="#cite_ref-:0_3-1">3.1</a></sup> <sup><a href="#cite_ref-:0_3-2">3.2</a></sup> <sup><a href="#cite_ref-:0_3-3">3.3</a></sup> <sup><a href="#cite_ref-:0_3-4">3.4</a></sup> <sup><a href="#cite_ref-:0_3-5">3.5</a></sup> <sup><a href="#cite_ref-:0_3-6">3.6</a></sup></span> <span class="reference-text">Yu-Wai-Man C, Arno G, Brookes J, Garcia-Feijoo J, Khaw
PT, Moosajee M. Primary congenital glaucoma including next-generation
sequencing-based approaches: clinical utility gene card. Eur J Hum Genet.
2018;26(11):1713-8.</span>
</li>
<li id="cite_note-:12-4"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:12_4-0">4.0</a></sup> <sup><a href="#cite_ref-:12_4-1">4.1</a></sup></span> <span class="reference-text">Neustein RF, Bruce BB, Beck AD. Primary Congenital
Glaucoma Versus Glaucoma Following Congenital Cataract Surgery: Comparative
Clinical Features and Long-term Outcomes. Am J Ophthalmol. 2016;170:214-22.</span>
</li>
<li id="cite_note-:13-5"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:13_5-0">5.0</a></sup> <sup><a href="#cite_ref-:13_5-1">5.1</a></sup></span> <span class="reference-text">Biglan AW, Hiles DA. The visual results following
infantile glaucoma surgery. J Pediatr Ophthalmol Strabismus. 1979;16(6):377-81.</span>
</li>
<li id="cite_note-:14-6"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:14_6-0">6.0</a></sup> <sup><a href="#cite_ref-:14_6-1">6.1</a></sup> <sup><a href="#cite_ref-:14_6-2">6.2</a></sup> <sup><a href="#cite_ref-:14_6-3">6.3</a></sup></span> <span class="reference-text">&#160;Shah M, Bouhenni R, Benmerzouga I. Geographical Variability in CYP1B1 Mutations in Primary Congenital Glaucoma. J Clin Med. 2022 Apr 6;11(7):2048. doi: 10.3390/jcm11072048. PMID: 35407656; PMCID: PMC8999900.</span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><a href="#cite_ref-7">↑</a></span> <span class="reference-text">Duke-Elder S. Congenital Deformities. St Louis: CV
Mosby; 1969. 548-65 p.</span>
</li>
<li id="cite_note-:4-8"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:4_8-0">8.0</a></sup> <sup><a href="#cite_ref-:4_8-1">8.1</a></sup> <sup><a href="#cite_ref-:4_8-2">8.2</a></sup> <sup><a href="#cite_ref-:4_8-3">8.3</a></sup> <sup><a href="#cite_ref-:4_8-4">8.4</a></sup> <sup><a href="#cite_ref-:4_8-5">8.5</a></sup></span> <span class="reference-text">DeLuise VP, Anderson DR. Primary infantile
glaucoma (Congenital glaucoma). Surv Ophthalmol. 1983;28:1-18</span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><a href="#cite_ref-9">↑</a></span> <span class="reference-text">Ohtake Y, Tanino T, Suzuki Y, Miyata H, Taomoto M,
Azuma N, et al. Phenotype of cytochrome P4501B1 gene (CYP1B1) mutations in
Japanese patients with primary congenital glaucoma. Br J Ophthalmol.
2003;87(3):302-4.</span>
</li>
<li id="cite_note-:2-10"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:2_10-0">10.0</a></sup> <sup><a href="#cite_ref-:2_10-1">10.1</a></sup></span> <span class="reference-text">Lewis CJ, Hedberg-Buenz A, DeLuca AP, Stone EM,
Alward WLM, Fingert JH. Primary congenital and developmental glaucomas. Hum Mol
Genet. 2017;26(R1):R28-R36.</span>
</li>
<li id="cite_note-:3-11"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:3_11-0">11.0</a></sup> <sup><a href="#cite_ref-:3_11-1">11.1</a></sup></span> <span class="reference-text">Online Mendelian Inheritance in Man, OMIM (TM). An
Online Catalog of Human Genes and Genetic Disorders 

Updated 20 January 2012 [Internet]. 2011.</span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><a href="#cite_ref-12">↑</a></span> <span class="reference-text">Bejjani BA, Xu L, Armstrong D, Lupski JR,
Reneker LW. Expression patterns of cytochrome P4501B1 (Cyp1b1) in FVB/N mouse
eyes. Exp Eye Res. 2002;75(3):249-57.</span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><a href="#cite_ref-13">↑</a></span> <span class="reference-text">Teixeira LB, Zhao Y, Dubielzig RR, Sorenson CM,
Sheibani N. Ultrastructural abnormalities of the trabecular meshwork
extracellular matrix in Cyp1b1-deficient mice. Vet Pathol. 2015;52(2):397-403.</span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><a href="#cite_ref-14">↑</a></span> <span class="reference-text">Williams AL, Eason J, Chawla B, Bohnsack BL.
Cyp1b1 Regulates Ocular Fissure Closure Through a Retinoic Acid-Independent
Pathway. Invest Ophthalmol Vis Sci. 2017;58(2):1084-97.</span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><a href="#cite_ref-15">↑</a></span> <span class="reference-text">&#160;Suri F, Yazdani S, Narooie-Nejhad M, Zargar SJ, Paylakhi SH, Zeinali S, Pakravan M, Elahi E. Variable expressivity and high penetrance of CYP1B1 mutations associated with primary congenital glaucoma. Ophthalmology. 2009 Nov;116(11):2101-9. doi: 10.1016/j.ophtha.2009.04.045. Epub 2009 Sep 10. PMID: 19744731.</span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><a href="#cite_ref-16">↑</a></span> <span class="reference-text">Alghamdi A, Aldossary W, Albahkali S, Alotaibi B, Alrfaei BM. The loss of microglia activities facilitates glaucoma progression in association with CYP1B1 gene mutation (p.Gly61Glu). PLoS One. 2020 Nov 10;15(11):e0241902. doi: 10.1371/journal.pone.0241902. PMID: 33170892; PMCID: PMC7654781.</span>
</li>
<li id="cite_note-:15-17"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:15_17-0">17.0</a></sup> <sup><a href="#cite_ref-:15_17-1">17.1</a></sup></span> <span class="reference-text">Schlotzer-Schrehardt U, Zenkel M, Kuchle M, Sakai
LY, Naumann GO. Role of transforming growth factor-beta1 and its latent form
binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001;73(6):765-80.</span>
</li>
<li id="cite_note-:16-18"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:16_18-0">18.0</a></sup> <sup><a href="#cite_ref-:16_18-1">18.1</a></sup></span> <span class="reference-text">Hyytiainen M, Keski-Oja J. Latent TGF-beta binding
protein LTBP-2 decreases fibroblast adhesion to fibronectin. J Cell Biol.
2003;163(6):1363-74.</span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><a href="#cite_ref-19">↑</a></span> <span class="reference-text">Rifkin DB. Latent transforming growth factor-beta
(TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol
Chem. 2005;280(9):7409-12.</span>
</li>
<li id="cite_note-20"><span class="mw-cite-backlink"><a href="#cite_ref-20">↑</a></span> <span class="reference-text">Souma T, Tompson SW, Thomson BR, Siggs OM,
Kizhatil K, Yamaguchi S, et al. Angiopoietin receptor TEK mutations underlie
primary congenital glaucoma with variable expressivity. J Clin Invest.
2016;126(7):2575-87.</span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><a href="#cite_ref-21">↑</a></span> <span class="reference-text">Thomson BR, Souma T, Tompson SW, Onay T, Kizhatil
K, Siggs OM, et al. Angiopoietin-1 is required for Schlemm's canal development
in mice and humans. J Clin Invest. 2017;127(12):4421-36.</span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><a href="#cite_ref-22">↑</a></span> <span class="reference-text">Qiao Y, Chen Y, Tan C, Sun X, Chen X, Chen J. Screening and Functional Analysis of TEK Mutations in Chinese Children With Primary Congenital Glaucoma. Front Genet. 2021 Dec 10;12:764509. doi: 10.3389/fgene.2021.764509. PMID: 34956319; PMCID: PMC8703195.</span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><a href="#cite_ref-23">↑</a></span> <span class="reference-text">Kaur K, Reddy AB, Mukhopadhyay A, Mandal AK,
Hasnain SE, Ray K, et al. Myocilin gene implicated in primary congenital
glaucoma. Clin Genet. 2005;67(4):335-40.</span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><a href="#cite_ref-24">↑</a></span> <span class="reference-text">Banerjee A, Chakraborty S, Chakraborty A,
Chakrabarti S, Ray K. Functional and Structural Analyses of CYP1B1 Variants
Linked to Congenital and Adult-Onset Glaucoma to Investigate the Molecular
Basis of These Diseases. PLoS One. 2016;11(5):e0156252.</span>
</li>
<li id="cite_note-25"><span class="mw-cite-backlink"><a href="#cite_ref-25">↑</a></span> <span class="reference-text">Mookherjee S, Acharya M, Banerjee D, Bhattacharjee
A, Ray K. Molecular basis for involvement of CYP1B1 in MYOC upregulation and
its potential implication in glaucoma pathogenesis. PLoS One. 2012;7(9):e45077.</span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><a href="#cite_ref-26">↑</a></span> <span class="reference-text">Vincent AL, Billingsley G, Buys Y, Levin AV,
Priston M, Trope G, et al. Digenic inheritance of early-onset glaucoma: CYP1B1,
a potential modifier gene. Am J Hum Genet. 2002;70(2):448-60.</span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><a href="#cite_ref-27">↑</a></span> <span class="reference-text">Kabra M, Zhang W, Rathi S, Mandal AK, Senthil S,
Pyatla G, et al. Angiopoietin receptor TEK interacts with CYP1B1 in primary
congenital glaucoma. Hum Genet. 2017;136(8):941-9.</span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><a href="#cite_ref-28">↑</a></span> <span class="reference-text">Worst JGF. The pathogenesis of congential
glaucoma.&#160; An embryological and
goniosurgical study. Springfield, Ill: Charles C. Thomas; 1966.</span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><a href="#cite_ref-29">↑</a></span> <span class="reference-text">Barkan O. Pathogenesis of congenital glaucoma:
gonioscopic and anatomic observation of the angle of the anterior chamber in
the normal eye and in congenital glaucoma. Am J Ophthalmol. 1955;40:1-11.</span>
</li>
<li id="cite_note-:5-30"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:5_30-0">30.0</a></sup> <sup><a href="#cite_ref-:5_30-1">30.1</a></sup></span> <span class="reference-text">Pilat AV, Proudlock FA, Shah S, Sheth V, Purohit
R, Abbot J, et al. Assessment of the anterior segment of patients with primary
congenital glaucoma using handheld optical coherence tomography. Eye (Lond).
2019;33(8):1232-9.</span>
</li>
<li id="cite_note-31"><span class="mw-cite-backlink"><a href="#cite_ref-31">↑</a></span> <span class="reference-text">Sampaolesi R, Argento C. Scanning electron
microscopy of the trabecular meshwork in normal and glucomatous eyes. Invest
Ophthalmol Vis Sci. 1977;16(4):302-14.</span>
</li>
<li id="cite_note-32"><span class="mw-cite-backlink"><a href="#cite_ref-32">↑</a></span> <span class="reference-text">Maul E, Strozzi L, Munoz C, Reyes C. The outflow
pathway in congenital glaucoma. Am J Ophthalmol. 1980;89(5):667-73.</span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><a href="#cite_ref-33">↑</a></span> <span class="reference-text">Tawara A, Inomata H. Developmental immaturity of
the trabecular meshwork in congenital glaucoma. Am J Ophthalmol.
1981;92(4):508-25.</span>
</li>
<li id="cite_note-:6-34"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:6_34-0">34.0</a></sup> <sup><a href="#cite_ref-:6_34-1">34.1</a></sup></span> <span class="reference-text">Garcia-Anton MT, Salazar JJ, de Hoz R, Rojas B,
Ramirez AI, Trivino A, et al. Goniodysgenesis variability and activity of
CYP1B1 genotypes in primary congenital glaucoma. PLoS One. 2017;12(4):e0176386.</span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><a href="#cite_ref-35">↑</a></span> <span class="reference-text">Maumenee AE. Further observations on the
pathogenesis of congenital glaucoma. Trans Am Ophthalmol Soc. 1962;60:140-6.</span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><a href="#cite_ref-36">↑</a></span> <span class="reference-text">Anderson DR. The development of the trabecular
meshwork and its abnormality in primary infantile glaucoma. Trans Am Ophthalmol
Soc. 1981;79:458-85.</span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><a href="#cite_ref-37">↑</a></span> <span class="reference-text">Kupfer C, Kaiser-Kupfer MI. Observations on the
development of the anterior chamber angle with reference to the pathogenesis of
congenital glaucomas. Am J Ophthalmol. 1979;88(3 Pt 1):424-6.</span>
</li>
<li id="cite_note-38"><span class="mw-cite-backlink"><a href="#cite_ref-38">↑</a></span> <span class="reference-text">Williams AL, Eason J, Chawla B, Bohnsack BL.
Cyp1b1 Regulates Ocular Fissure Closure Through a Retinoic Acid-Independent
Pathway. Invest Ophthalmol Vis Sci. 2017;58(2):1084-97.</span>
</li>
<li id="cite_note-39"><span class="mw-cite-backlink"><a href="#cite_ref-39">↑</a></span> <span class="reference-text">Walton DS. Diagnosis and treatment of glaucoma in
childhood. In: Epstein DL, editor. Chandler and Grant's Glaucoma. 3rd ed.
Phila: Lea &amp; Febinger; 1986.</span>
</li>
<li id="cite_note-40"><span class="mw-cite-backlink"><a href="#cite_ref-40">↑</a></span> <span class="reference-text">Morin JD, Bryars JH. Causes of loss of vision in
congenital glaucoma. Arch Ophthalmol. 1980;98(9):1575-6.</span>
</li>
<li id="cite_note-41"><span class="mw-cite-backlink"><a href="#cite_ref-41">↑</a></span> <span class="reference-text">Kiskis AA, Markowitz SN, Morin JD. Corneal
diameter and axial length in congenital glaucoma. Can J Opththalmol.
1985;20:93.</span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><a href="#cite_ref-42">↑</a></span> <span class="reference-text">Kessing SV, Gregersen E. The distended disc in
early stages of congenital glaucoma. Acta Ophthalmol (Copenh).
1977;55(3):431-5.</span>
</li>
<li id="cite_note-43"><span class="mw-cite-backlink"><a href="#cite_ref-43">↑</a></span> <span class="reference-text">Quigley HA. The pathogenesis of reversible cupping
in congenital glaucoma. Am J Ophthalmol. 1977;84(3):358-70.</span>
</li>
<li id="cite_note-44"><span class="mw-cite-backlink"><a href="#cite_ref-44">↑</a></span> <span class="reference-text">Ely AL, El-Dairi MA, Freedman SF. Cupping reversal
in pediatric glaucoma--evaluation of the retinal nerve fiber layer and visual
field. Am J Ophthalmol. 2014;158(5):905-15.</span>
</li>
<li id="cite_note-45"><span class="mw-cite-backlink"><a href="#cite_ref-45">↑</a></span> <span class="reference-text">Fayed MA, Chen TC. Pediatric intraocular pressure
measurements: Tonometers, central corneal thickness, and anesthesia. Surv
Ophthalmol. 2019.</span>
</li>
<li id="cite_note-46"><span class="mw-cite-backlink"><a href="#cite_ref-46">↑</a></span> <span class="reference-text">Eisenberg DL, Sherman BG, McKeown CA, Schuman JS.
Tonometry in adults and children. A manometric evaluation of pneumatonometry,
applanation, and TonoPen in vitro and in vivo. Ophthalmology.
1998;105(7):1173-81.</span>
</li>
<li id="cite_note-47"><span class="mw-cite-backlink"><a href="#cite_ref-47">↑</a></span> <span class="reference-text">Grigorian F, Grigorian AP, Olitsky SE. The use of
the iCare tonometer reduced the need for anesthesia to measure intraocular
pressure in children. J Aapos. 2012;16(6):508-10.</span>
</li>
<li id="cite_note-48"><span class="mw-cite-backlink"><a href="#cite_ref-48">↑</a></span> <span class="reference-text">Flemmons MS, Hsiao YC, Dzau J, Asrani S, Jones S,
Freedman SF. Icare rebound tonometry in children with known and suspected
glaucoma. J Aapos. 2011;15(2):153-7.</span>
</li>
<li id="cite_note-49"><span class="mw-cite-backlink"><a href="#cite_ref-49">↑</a></span> <span class="reference-text">McKee EC, Ely AL, Duncan JE, Dosunmu EO,
Freedman SF. A comparison of Icare PRO and Tono-Pen XL tonometers in
anesthetized children. J aapos. 2015;19(4):332-7.</span>
</li>
<li id="cite_note-50"><span class="mw-cite-backlink"><a href="#cite_ref-50">↑</a></span> <span class="reference-text">Gupta S, Mahalingam K, Singh A, Selvan H, Somarajan BI, Gupta V. Posterior corneal morphological changes in primary congenital glaucoma. Indian J Ophthalmol. 2022 Jul;70(7):2571-2577. doi: 10.4103/ijo.IJO_317_22. PMID: 35791159.</span>
</li>
<li id="cite_note-:7-51"><span class="mw-cite-backlink"><a href="#cite_ref-:7_51-0">↑</a></span> <span class="reference-text">Sampaolesi R, Caruso R. Ocular Echometry in the Diagnosis of Congenital Glaucoma.&#160;<em>Arch Ophthalmol.</em>&#160;1982;100(4):574–577.&#160;</span>
</li>
<li id="cite_note-52"><span class="mw-cite-backlink"><a href="#cite_ref-52">↑</a></span> <span class="reference-text">Henriques MJ, Vessani RM,
Reis FA, de Almeida GV, Betinjane AJ, Susanna R, Jr. Corneal thickness in
congenital glaucoma. J Glaucoma. 2004;13(3):185-8.</span>
</li>
<li id="cite_note-:10-53"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:10_53-0">53.0</a></sup> <sup><a href="#cite_ref-:10_53-1">53.1</a></sup></span> <span class="reference-text">Doozandeh A, Yazdani S, Ansari S, Pakravan M, Motevasseli T, Hosseini B, Yasseri M. Corneal profile in primary congenital glaucoma. Acta Ophthalmol. 2017;95(7):e575-e581.</span>
</li>
<li id="cite_note-:11-54"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:11_54-0">54.0</a></sup> <sup><a href="#cite_ref-:11_54-1">54.1</a></sup></span> <span class="reference-text">
    Zareei A, Razeghinejad MR, Salouti R. Corneal Biomechanical Properties and Thickness in Primary Congenital Glaucoma and Normal Eyes: A Comparative Study. Med Hypothesis Discov Innov
Ophthalmol. 2018;7(2):68-72.
  </span>
</li>
<li id="cite_note-55"><span class="mw-cite-backlink"><a href="#cite_ref-55">↑</a></span> <span class="reference-text">Donahue SP, Porter A. SITA visual field testing in children. J
AAPOS. 2001;5:114.</span>
</li>
<li id="cite_note-56"><span class="mw-cite-backlink"><a href="#cite_ref-56">↑</a></span> <span class="reference-text">Salchow DJ, Oleynikov YS, Chiang MF,
Kennedy-Salchow SE, Langton K, Tsai JC, et al. Retinal nerve fiber layer
thickness in normal children measured with optical coherence tomography.
Ophthalmology. 2006;113(5):786-91.</span>
</li>
<li id="cite_note-57"><span class="mw-cite-backlink"><a href="#cite_ref-57">↑</a></span> <span class="reference-text">Ahn HC, Son HW, Kim JS, Lee JH. Quantitative
analysis of retinal nerve fiber layer thickness of normal children and
adolescents. Korean J Ophthalmol. 2005;19(3):195-200.</span>
</li>
<li id="cite_note-58"><span class="mw-cite-backlink"><a href="#cite_ref-58">↑</a></span> <span class="reference-text">Hess DB, Asrani SG, Bhide MG, Enyedi LB, Stinnett
SS, Freedman SF. Macular and retinal nerve fiber layer analysis of normal and
glaucomatous eyes in children using optical coherence tomography. Am J
Ophthalmol. 2005;139(3):509-17.</span>
</li>
<li id="cite_note-59"><span class="mw-cite-backlink"><a href="#cite_ref-59">↑</a></span> <span class="reference-text">Rao A, Sahoo B, Kumar M, Varshney G, Kumar R.
Retinal nerve fiber layer thickness in children &lt;18 years by spectral-domain
optical coherence tomography. Semin Ophthalmol. 2013;28(2):97-102.</span>
</li>
<li id="cite_note-60"><span class="mw-cite-backlink"><a href="#cite_ref-60">↑</a></span> <span class="reference-text">Rotruck JC, House RJ, Freedman SF, Kelly MP,
Enyedi LB, Prakalapakorn SG, et al. Optical Coherence Tomography normative
peripapillary retinal nerve fiber layer and macular data in children ages 0-5
years. Am J Ophthalmol. 2019.</span>
</li>
<li id="cite_note-61"><span class="mw-cite-backlink"><a href="#cite_ref-61">↑</a></span> <span class="reference-text">Hsu ST, Chen X, Ngo HT, House RJ, Kelly MP, Enyedi
LB, et al. Imaging Infant Retinal Vasculature with OCT Angiography. Ophthalmol
Retina. 2019;3(1):95-6.</span>
</li>
<li id="cite_note-62"><span class="mw-cite-backlink"><a href="#cite_ref-62">↑</a></span> <span class="reference-text">Pearce WG. Autosomal dominant megalocornea with
congenital glaucoma: evidence for germ-line mosaicism. Can J Ophthalmol.
1991;26(1):21-6.</span>
</li>
<li id="cite_note-63"><span class="mw-cite-backlink"><a href="#cite_ref-63">↑</a></span> <span class="reference-text">Greco, A. et al., 2022, 'Childhood Glaucoma and Medical Treatment: An Up to Date', in G. L. Giudice (ed.), Vision Correction and Eye Surgery, IntechOpen, London. 10.5772/intechopen.100579.</span>
</li>
<li id="cite_note-64"><span class="mw-cite-backlink"><a href="#cite_ref-64">↑</a></span> <span class="reference-text">Coppens G, Stalmans I, Zeyen T, Casteels I. The safety and efficacy of glaucoma medication in the pediatric population. J Pediatr Ophthalmol Strabismus. 2009 Jan-Feb;46(1):12-8. doi: 10.3928/01913913-20090101-05. PMID: 19213271.</span>
</li>
<li id="cite_note-65"><span class="mw-cite-backlink"><a href="#cite_ref-65">↑</a></span> <span class="reference-text">Buckley MM, Goa KL, Clissold SP. Ocular Betaxolol. A Review of Its
Pharmacological Properties, and Therapeutic Efficacy in Glaucoma and Ocular
Hypertension. Drugs. 1990;40:75-90. </span>
</li>
<li id="cite_note-66"><span class="mw-cite-backlink"><a href="#cite_ref-66">↑</a></span> <span class="reference-text">Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci. 1977;16(8):730-742.</span>
</li>
<li id="cite_note-67"><span class="mw-cite-backlink"><a href="#cite_ref-67">↑</a></span> <span class="reference-text">Capino AC, Dannaway DC, Miller JL. Metabolic
Acidosis with Ophthalmic Dorzolamide in a Neonate. J Pediatr Pharmacol Ther.
2016;21(3):256-9.</span>
</li>
<li id="cite_note-68"><span class="mw-cite-backlink"><a href="#cite_ref-68">↑</a></span> <span class="reference-text">Maeda-Chubachi T, Chi-Burris K, Simons BD,
Freedman SF, Khaw PT, Wirostko B, et al. Comparison of latanoprost and timolol
in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked
multicenter study. Ophthalmology. 2011;118(10):2014-21.</span>
</li>
<li id="cite_note-69"><span class="mw-cite-backlink"><a href="#cite_ref-69">↑</a></span> <span class="reference-text">Kim JS, Blizzard S, Woodward JA, Leyngold IM, Liss J, Freedman SF. Prostaglandin-Associated Periorbitopathy in Children and Young Adults with Glaucoma. Ophthalmol Glaucoma. In Press. Available online 3 April 2020.</span>
</li>
<li id="cite_note-70"><span class="mw-cite-backlink"><a href="#cite_ref-70">↑</a></span> <span class="reference-text">El Sayed Y, Esmael A,
Mettias N, El Sanabary Z, Gawdat G. Factors influencing the outcome of
goniotomy and trabeculotomy in primary congenital glaucoma. Br J Ophthalmol. <time>2019 Mar 7</time>
[Online ahead of print]</span>
</li>
<li id="cite_note-71"><span class="mw-cite-backlink"><a href="#cite_ref-71">↑</a></span> <span class="reference-text">Huang H, Bao WJ,
Yamamoto T, Kawase K, Sawada A. Postoperative outcome of three different
procedures for childhood glaucoma. Clin Ophthalmol. 2019;13:1-7.</span>
</li>
<li id="cite_note-72"><span class="mw-cite-backlink"><a href="#cite_ref-72">↑</a></span> <span class="reference-text">Mandal AK, Gothwal VK, Nutheti R. Surgical outcome
of primary developmental glaucoma: a single surgeon's long-term experience from
a tertiary eye care centre in India. Eye. 2007;21(6):764-74.</span>
</li>
<li id="cite_note-73"><span class="mw-cite-backlink"><a href="#cite_ref-73">↑</a></span> <span class="reference-text">Khalil DH, Abdelhakim MA. Primary trabeculotomy
compared to combined trabeculectomy-trabeculotomy in congenital glaucoma:
3-year study. Acta Ophthalmol. 2016;94(7):e550-e4.</span>
</li>
<li id="cite_note-74"><span class="mw-cite-backlink"><a href="#cite_ref-74">↑</a></span> <span class="reference-text">Jayaram H, Scawn R, Pooley F, Chiang M, Bunce C,
Strouthidis NG, et al. Long-Term Outcomes of Trabeculectomy Augmented with
Mitomycin C Undertaken within the First 2 Years of Life. Ophthalmology.
2015;122(11):2216-22.</span>
</li>
<li id="cite_note-75"><span class="mw-cite-backlink"><a href="#cite_ref-75">↑</a></span> <span class="reference-text">Khaw PT, Chiang M, Shah P, Sii F, Lockwood A,
Khalili A. Enhanced trabeculectomy: the Moorfields Safer Surgery System. Dev
Ophthalmol. 2012;50:1-28.</span>
</li>
<li id="cite_note-76"><span class="mw-cite-backlink"><a href="#cite_ref-76">↑</a></span> <span class="reference-text">Low S, Hamada S, Nischal KK. Antimetabolite and
releasable suture augmented filtration surgery in refractory pediatric
glaucomas. J Aapos. 2008;12(2):166-72.</span>
</li>
<li id="cite_note-77"><span class="mw-cite-backlink"><a href="#cite_ref-77">↑</a></span> <span class="reference-text">Beck AD, Wilson WR, Lynch MG, Lynn MJ, Noe R.
Trabeculectomy with adjunctive Mitomycin c in pediatric glaucoma. Am J
Ophthalmol. 1998;126:648-57.</span>
</li>
<li id="cite_note-78"><span class="mw-cite-backlink"><a href="#cite_ref-78">↑</a></span> <span class="reference-text">Margeta MA, Kuo AN, Proia AD, Freedman SF. Staying
away from the optic nerve: a formula for modifying glaucoma drainage device
surgery in pediatric and other small eyes. J aapos. 2017;21(1):39-43.e1.</span>
</li>
<li id="cite_note-79"><span class="mw-cite-backlink"><a href="#cite_ref-79">↑</a></span> <span class="reference-text">Ishida K, Mandal AK, Netland PA. Glaucoma
Drainage Implants in Pediatric Patients. Ophthalmol Clin North Am.
2005;18:431-42.</span>
</li>
<li id="cite_note-80"><span class="mw-cite-backlink"><a href="#cite_ref-80">↑</a></span> <span class="reference-text">Tung I, Marcus I, Thiamthat W, Freedman SF. Second
glaucoma drainage devices in refractory pediatric glaucoma: failure by
fibrovascular ingrowth. Am J Ophthalmol. 2014;158(1):113-7.</span>
</li>
<li id="cite_note-81"><span class="mw-cite-backlink"><a href="#cite_ref-81">↑</a></span> <span class="reference-text">Cunliffe IA, Molteno AC. Long-term follow-up of
Molteno drains used in the treatment of glaucoma presenting in childhood. Eye.
1998;12(Pt 3a):379-85.</span>
</li>
<li id="cite_note-82"><span class="mw-cite-backlink"><a href="#cite_ref-82">↑</a></span> <span class="reference-text">Beck AD, Freedman S, Kammer J, Jin J. Aqueous
shunt devices compared with trabeculectomy with Mitomycin-C for children in the
first two years of life. Am J Ophthalmol. 2003;136(6):994-1000.</span>
</li>
<li id="cite_note-83"><span class="mw-cite-backlink"><a href="#cite_ref-83">↑</a></span> <span class="reference-text">Tai AX, Song JC. Surgical outcomes of Baerveldt
implants in pediatric glaucoma patients. J AAPOS. 2014;18(6):550-3.</span>
</li>
<li id="cite_note-84"><span class="mw-cite-backlink"><a href="#cite_ref-84">↑</a></span> <span class="reference-text">Mandalos A, Tailor R, Parmar T, Sung V. The
Long-term Outcomes of Glaucoma Drainage Device in Pediatric Glaucoma. J
Glaucoma. 2016;25(3):e189-95.</span>
</li>
<li id="cite_note-85"><span class="mw-cite-backlink"><a href="#cite_ref-85">↑</a></span> <span class="reference-text">Razeghinejad MR, Kaffashan S, Nowroozzadeh MH.
Results of Ahmed glaucoma valve implantation in primary congenital glaucoma. J
aapos. 2014;18(6):590-5.</span>
</li>
<li id="cite_note-86"><span class="mw-cite-backlink"><a href="#cite_ref-86">↑</a></span> <span class="reference-text">Pakravan M, Esfandiari H, Yazdani S, Doozandeh A,
Dastborhan Z, Gerami E, et al. Clinical outcomes of Ahmed glaucoma valve
implantation in pediatric glaucoma. Eur J Ophthalmol. 2019;29(1):44-51.</span>
</li>
<li id="cite_note-87"><span class="mw-cite-backlink"><a href="#cite_ref-87">↑</a></span> <span class="reference-text">Abdelrahman AM, El Sayed YM. Micropulse Versus
Continuous Wave Transscleral Cyclophotocoagulation in Refractory Pediatric
Glaucoma. J Glaucoma. 2018;27(10):900-5.</span>
</li>
<li id="cite_note-88"><span class="mw-cite-backlink"><a href="#cite_ref-88">↑</a></span> <span class="reference-text">Way AL, Nischal KK. High-frequency
ultrasound-guided transscleral diode laser cyclophotocoagulation. Br J
Ophthalmol. 2014;98(7):992-4.</span>
</li>
<li id="cite_note-89"><span class="mw-cite-backlink"><a href="#cite_ref-89">↑</a></span> <span class="reference-text">Bock CJ, Freedman SF, Buckley EG, Shields MB.
Transscleral diode laser cyclophotocoagulation for refractory pediatric
glaucomas. J Pediatr Ophthalmol Strabismus. 1997;34(4):235-9.</span>
</li>
<li id="cite_note-:8-90"><span class="mw-cite-backlink"><a href="#cite_ref-:8_90-0">↑</a></span> <span class="reference-text">Kirwan JF, Shah P, Khaw PT. Diode laser
cyclophotocoagulation: role in the management of refractory pediatric
glaucomas. Ophthalmology. 2002;109(2):316-23.</span>
</li>
<li id="cite_note-:9-91"><span class="mw-cite-backlink"><a href="#cite_ref-:9_91-0">↑</a></span> <span class="reference-text">Autrata R, Rehurek J. Long-term results of
transscleral cyclophotocoagulation in refractory pediatric glaucoma patients.
Ophthalmologica. 2003;217(6):393-400.</span>
</li>
<li id="cite_note-92"><span class="mw-cite-backlink"><a href="#cite_ref-92">↑</a></span> <span class="reference-text">Sood S, Beck AD. Cyclophotocoagulation
versus sequential tube shunt as a secondary intervention following primary tube
shunt failure in pediatric glaucoma. J Aapos. 2009;13(4):379-83.</span>
</li>
<li id="cite_note-93"><span class="mw-cite-backlink"><a href="#cite_ref-93">↑</a></span> <span class="reference-text">Neely DE, Plager DA. Endocyclophotocoagulation for
management of difficult pediatric glaucomas. J Aapos. 2001;5(4):221-9.</span>
</li>
<li id="cite_note-94"><span class="mw-cite-backlink"><a href="#cite_ref-94">↑</a></span> <span class="reference-text">Glaser TS, Mulvihill MS, Freedman SF. Endoscopic
cyclophotocoagulation (ECP) for childhood glaucoma: a large single-center
cohort experience. J AAPOS. 2019;23(2):84 e1- e7.</span>
</li>
<li id="cite_note-95"><span class="mw-cite-backlink"><a href="#cite_ref-95">↑</a></span> <span class="reference-text">Baig NB, Lin AA,
Freedman SF. Ultrasound evaluation of glaucoma drainage devices in children. J
AAPOS. 2015;19(3):281-4.</span>
</li>
<li id="cite_note-96"><span class="mw-cite-backlink"><a href="#cite_ref-96">↑</a></span> <span class="reference-text">Shaffer RN. Prognosis of goniotomy in primary
infantile glaucoma (trabeculodysgenesis). Trans Am Ophthalmol Soc.
1982;80:321-5.</span>
</li>
<li id="cite_note-97"><span class="mw-cite-backlink"><a href="#cite_ref-97">↑</a></span> <span class="reference-text">Kantipuly A, Pillai MR, Shroff S, Khatiwala R,
Raman GV, Krishnadas SR, et al. Caregiver Burden in Primary Congenital
Glaucoma. Am J Ophthalmol. 2019.</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035202
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0 seconds
CPU time usage: 0.445 seconds
Real time usage: 2.799 seconds
Preprocessor visited node count: 2239/1000000
Post‐expand include size: 15027/2097152 bytes
Template argument size: 3853/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 1/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 11807/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00% 1499.269      1 -total
 88.51% 1327.044      1 Template:Article
 85.24% 1278.014      8 Template:Infobox_section
 50.75%  760.920     22 Template:UserLookup
 11.48%  172.133      1 Template:Infobox_disease
  5.28%   79.216      1 Template:Review_expired
  2.63%   39.370      2 Template:Infobox_end
  0.39%    5.820      2 Template:Infobox_begin
  0.15%    2.186      1 Template:Get_active_contest
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Primary_Congenital_Glaucoma&amp;oldid=89564">https://eyewiki.org/w/index.php?title=Primary_Congenital_Glaucoma&amp;oldid=89564</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li><li><a href="/Category:Pediatric_Ophthalmology/Strabismus" title="Category:Pediatric Ophthalmology/Strabismus">Pediatric Ophthalmology/Strabismus</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzz04837">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Primary_Congenital_Glaucoma" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Primary_Congenital_Glaucoma" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Primary_Congenital_Glaucoma&amp;oldid=89564" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Primary_Congenital_Glaucoma&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on February 10, 2023, at 10:48.</div>
					<div>This page has been accessed 252,638 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0},"limitreport":{"cputime":"0.445","walltime":"2.799","ppvisitednodes":{"value":2239,"limit":1000000},"postexpandincludesize":{"value":15027,"limit":2097152},"templateargumentsize":{"value":3853,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":1,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":11807,"limit":5000000},"timingprofile":["100.00% 1499.269      1 -total"," 88.51% 1327.044      1 Template:Article"," 85.24% 1278.014      8 Template:Infobox_section"," 50.75%  760.920     22 Template:UserLookup"," 11.48%  172.133      1 Template:Infobox_disease","  5.28%   79.216      1 Template:Review_expired","  2.63%   39.370      2 Template:Infobox_end","  0.39%    5.820      2 Template:Infobox_begin","  0.15%    2.186      1 Template:Get_active_contest"]},"cachereport":{"timestamp":"20230306035202","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":3527});});</script></body>
</html>